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3Abstract
Catechol structures can be found in many endogenous compounds including catechol-
amines and catechol estrogens and in various drugs and drug candidates. Catecholic hy-
droxyls provide reactive groups for phase II metabolic enzymes of which different
forms of UGTs, SULTs and COMTs compete for their conjugation. Little is known,
however, about the factors determining the substrate acceptance of these enzymes and
their relative contribution to the metabolism of catechols with diverse structures.
In this study, two novel analytical methods were developed: an HPTLC method
combining radioactivity measurement and densitometry for the assay of UGT, and a ra-
diochemical HPLC method for the assay of COMT. The respective methods were util-
ised in studying the glucuronidation properties of a set of nitrocatechols in rat liver mi-
crosomes and in determining the apparent enzyme kinetic parameters of methylation for
41 structurally diverse catechols catalysed by human recombinant S-COMT. In addi-
tion, the in vitro glucuronidation of the COMT inhibitors entacapone and tolcapone was
compared by determining the kinetic parameters using human liver microsomes and the
relevant human recombinant UGT isoforms.
The results on the glucuronidation of nitrocatechols indicated that although they may
be excellent UGT substrates, this property is greatly affected by the nature and position
of substituents. Tolcapone was a slightly better substrate than entacapone in rat liver
microsomes, whereas entacapone showed a 14-fold V
max
/K
m
 value in human liver micro-
somes. Consequently, rat might be a poor animal model in predicting the glucuronida-
tion of this type of compound in humans. The higher glucuronidation rate of entacapone
compared with tolcapone in human microsomes may explain part of its approximately
seven times faster elimination half-life in vivo. Both compounds, especially entacapone,
were excellent substrates of UGT1A9, which knowledge may be useful in evaluating
risks for metabolic interactions.
A great variation was detected in the methylation ability of structurally diverse cate-
chols. For instance, among drugs used in the treatment of Parkinson’s disease no meth-
ylation of entacapone or tolcapone was observed, L-dopa and carbidopa appeared to be
poor COMT substrates, whereas benserazide exhibited a relatively high affinity and re-
activity. The best endogenous substrate was 2-hydroxyestradiol. For QSAR analysis,
the experimental data were combined with the calculation of substituent physico-
chemical properties and modelling of the compounds to the active site of rat S-COMT.
The most decisive factor increasing affinity and simultaneously decreasing reactivity
was the electron-withdrawing effect of substituents. In general, hydrophobic substitu-
ents increased and hydrophilic groups reduced the affinity, but the orientation of the
side chains greatly affected the extent of interactions formed with the hydrophobic sur-
roundings of the binding site. Most important of the several ortho-effects discovered,
that bulky ortho-substituents worsened affinity and reactivity, was demonstrated by
apomorphine that was not methylated under the conditions applied. Predictive models
for affinity and reactivity were constructed, and they may be utilised, in conjunction
with modelling of the active site, in assessing interactions between endogenous cate-
chols and catecholic drugs and in designing catecholic drugs with controlled metabolic
methylation.
41. Introduction
Once an orally administered drug has entered the body, it has to be absorbed, distrib-
uted, metabolised and finally excreted. All these stages can have a significant effect on
the bioavailability of the drug and must be taken into account in drug development (Lin
and Lu, 1997). Although drugs may be extensively excreted as such by the kidney, most
drugs undergo some kind of metabolic transformation before excretion. Metabolic reac-
tions can be divided into phase I and phase II reactions (Gibson and Skett, 1994). Phase
I reactions, such as oxidation, reduction or hydrolysis, produce functional groups that
are subsequently capable of conjugation in phase II reactions. Conjugation with en-
dogenous compounds usually results in more water-soluble molecules, which facilitates
excretion in the bile and urine. The most important enzyme family catalysing phase I
reactions is cytochrome P-450 (CYP). UDP-glucuronosyltransferases (UGTs), sulpho-
transferases (SULTs), glutathione-S-transferases (GSTs) and different acetyltransferases
and methyltransferases are mainly responsible for the phase II reactions. Different en-
zymes and enzyme families may contribute to the metabolism of a given drug and the
rate and route can greatly affect the duration of action and safety of the drug. Besides
poor absorption, inappropriate metabolism is one of the main reasons preventing the
clinical use of many promising drug candidates (Prentis et al., 1988).
Due to the complexity of metabolic enzymes and the many internal and external
factors influencing them, the rate and route of metabolism is difficult to predict (Lin and
Lu, 1997). Metabolic studies are traditionally initiated by measuring the elimination
half-life of a drug candidate in laboratory animals and identifying the metabolites from
plasma and urine samples. However, numerous examples show that remarkable differ-
ences exist between species and problems in metabolism may appear only in admini-
stration to humans. The increasing availability of human tissues and the advances of
gene technology in producing individual enzymes have brought in vitro methods to
routine use in drug metabolism studies. In vitro studies are suited for early assessment
of metabolism and selection of the animal model for toxicity studies and for identifica-
tion of the individual enzyme forms contributing to the metabolism of a drug candidate.
In vitro data may be further utilised in drug interaction studies and sometimes even in
predicting in vivo clearance.
Cloning and expression of individual human enzymes that catalyse metabolic reac-
tions has enabled investigations on their structures and mechanisms underlying their
catalytical actions and substrate selectivities (Lin and Lu, 1997). At the moment, it is
not possible to predict metabolism on the basis of molecular structure, yet the ability to
control affinity to certain metabolic enzymes or alter the rate of metabolism by rational
structure modification would be useful in the drug discovery and development process.
In order to aspire after that goal, however, great efforts in investigating individual en-
zyme forms and other factors influencing drug metabolism in vivo are required.
In this study in vitro methods have been utilised in the study of the glucuronidation
of nitrocatecholic catechol O-methyltransferase (COMT) inhibitors and in the develop-
ment of predictive models for methylation catalysed by human soluble COMT.
52. Review of the literature
2.1. Role of conjugation reactions in drug and
xenobiotic metabolism
Phase II enzymes play an important role in the biotransformation of endogenous and
xenobiotic compounds to more easily excretable forms as well as in the metabolic inac-
tivation of pharmacologically active compounds. An especially important function is to
detoxify carcinogenic compounds formed in phase I reactions. For example, carcino-
genic diol epoxides, formed in phase I reactions from polycyclic aromatic hydrocar-
bons, are normally conjugated with glutathione and thereby readily excreted from the
body (Guengerich, 1992). However, reduced capacity of the phase II enzymes may lead
to the appearance of toxic compounds. For instance, 2-hydroxybiphenyl, an antimicro-
bial agent used to protect edible crops, is metabolised to non-toxic glucuronide and sul-
phate conjugates at low doses, whereas at high doses these pathways become saturated
and oxidative metabolism starts to produce toxic compounds capable of initiating blad-
der cancer (Reitz et al., 1983). Although phase II reactions are basically detoxifying, the
formed conjugates may also mediate adverse effects, for example acting as carriers for
carcinogenic compounds. 2-Naphthylamine, found in cigarette smoke, is N-
hydroxylated to a carcinogen in the liver, but subsequently glucuronidated to inactive
N-hydroxy-N-glucuronide. The glucuronide is, however, hydrolysed in the slightly
acidic environment of the bladder and decomposed to a nitrenium ion that can bind to
DNA and initiate cancer (Kadlubar et al., 1981, Miller and Miller, 1981). The site of
conjugation may have undesirable effects, for example biotransformation of a drug to a
more hydrophilic conjugate in the gastrointestinal tract usually deteriorates its absorp-
tion. A special case of potentially harmful phase II metabolites is 1-O-acylglucuronides
in which UDP-glucuronic acid is conjugated with a carboxyl acid group by ester link-
age. These compounds are chemically labile and the glucuronic acid moiety may be
displaced by nucleophiles. This leads to either hydrolysis of the glucuronide, in-
tramolecular rearrangement by acyl migration or intermolecular transacylation. Cova-
lent binding of 1-O-acylglucuronides and ester isomers to proteins by transacylation, or
glycosylation, are suspected to cause cytotoxicity, carcinogenecity and allergic reactions
(Fenselau, 1994).
The fact that interindividual differences in metabolic response occur is not related to
phase I enzymes only, but external as well as internal factors including age, sex, dis-
eases and genetics are known to influence also phase II enzymes. A well-known exam-
ple of the effect of age on glucuronidation is the 'grey baby' syndrome that is caused by
the decreased excretion of chloramphenicol glucuronide in new-borns (Weiss et al.,
1960). In old age the metabolic clearance sometimes declines, but this is caused more
likely by the lowered liver blood flow than by the decreased activity of metabolic en-
zymes (Miners and Mackenzie, 1991). However, decreased clearance of codeine to its
6-O-glucuronide has been observed in the elderly (Bochner et al., 1990). Higher capac-
ity in males than in females for glucuronidation of some drugs, including paracetamol
(Abernethy et al., 1982, Miners et al., 1983) diflunisal (Macdonald et al., 1990) and
propranolol (Walle et al., 1989), has been reported suggesting that the activity of some
UGTs may be affected by sex hormones. Risks for adverse effects caused by polymor-
phism in drug-metabolising enzymes are mainly associated with the CYP isoforms.
6However, many phase II metabolic enzymes are genetically polymorphic as well, the
most familiar being N-acetyltransferase (NAT). Polymorphism of this enzyme was first
discovered when isoniazid was used in the treatment of tuberculosis (Evans et al.,
1960). The incidence of rapid and slow acetylators varies considerably between both
ethnic groups and individuals in these groups, giving rise to different metabolic re-
sponses towards drugs metabolised via NAT (Evans, 1989). Other phase II metabolic
enzymes exhibiting genetically polymorphic forms include GST (Laisney et al., 1984),
COMT (Weinshilboum, 1984, 1988, Boudiková et al, 1990, Grossman et al., 1992),
UGT (Clarke and Burchell, 1994) SULT (Coughtrie et al., 1999) and thiopurine meth-
yltransferase (Weinshilboum and Sladek, 1980). Numerous studies suggesting their
contribution to diseases and variations in drug responses have been carried out, but the
clinical significance of most of the polymorphic phase II enzymes remains rather un-
clear.
External factors causing interindividual variations in drug metabolism include
smoking, medication, nutrition and environmental chemicals (Pelkonen and Breimer,
1994). Binding of polycyclic aromatic hydrocarbons, abundant in tobacco smoke, to the
corresponding receptor (Ah) has been found to induce not only certain CYP forms
(Whitlock et al., 1996) but also some UGTs and GSTs (Bock et al., 1990). For example,
heavy smoking has been reported to accelerate the glucuronidation of mexiletine and
propranolol by 30 and 55%, respectively (Grech-Bélanger et al. 1985, Walle et al.,
1987). Certain drugs are able to induce or inhibit some phase II metabolic enzymes
thereby increasing or decreasing the plasma clearance of other drugs metabolised via
the same enzymes. For instance, the anticonvulsant agents phenobarbitone, phenytoin
and carbamazepine are known to enhance the glucuronidation of various drugs includ-
ing oxazepam, paracetamol and valproic acid, (Scott et al., 1983, Miners et al., 1984,
Panesar et al., 1989), while probenecid has been found to inhibit the glucuronidation of
many drugs, especially those forming acyl glucuronides (Miners and Mackenzie, 1991).
Although metabolism normally inactivates a drug and transforms it to an easily ex-
cretable form, in some cases a metabolite has been even more potent than the parent
compound. Two well-known examples of phase II metabolites exhibiting high pharma-
cological activity are the N-sulphate conjugate of minoxidil (Johnson et al., 1982),
which, rather than minoxidil itself, causes the relaxation of smooth muscles (Kauffman
et al., 1994), and morphine 6-O-glucuronide, which is a more potent mu-opioid receptor
agonist than morphine (Pasternak et al., 1987, Paul et al., 1989, Frances et al., 1990).
Entero-hepatic circulation, in which the formed glucuronide is excreted in the intestine,
hydrolysed by bacterial β-glucuronidase, reabsorbed, and transported back to the liver,
may markedly prolong the pharmacological action of a drug. Even though the most
common reason for prodrug design is to enhance the absorption of hydrophilic drugs,
also glucuronide conjugates have been developed as prodrug candidates. For example, a
glucuronide conjugate of p-hydroxyaniline mustard, delivered in conjunction with the
hydrolytic, tumour-targeted β-glucuronidase, has been tested for its ability to kill tu-
mour cells (Cheng et al., 1999).
In addition to prodrug discovery, drug designers have recently been able to take ad-
vantage of metabolic reactions using another approach. In Parkinson’s disease, where
the symptoms are caused by the lack of dopamine in the striatum, patients have gener-
ally been treated with L-dopa, a dopamine precursor capable of penetrating the blood-
brain barrier. To decrease the decarboxylation of L-dopa to dopamine already in the pe-
riphery, it is normally administered in conjunction with a dopa decarboxylase (DDC)
inhibitor (benserazide or carbidopa) (Männistö et al., 1992). However, when DDC is
inhibited, the predominant metabolic pathway of L-dopa turns out to be the COMT-
7catalysed methylation of the hydroxyl in the 3 position. The formed 3-O-methyldopa
may be harmful to the patients (Männistö et al., 1992), may compete with L-dopa for
transport through the blood-brain barrier (Muenter et al., 1973, Wade and Katzman,
1975) and be a substrate of brain DDC, thereby competing with L-dopa for biotrans-
formation to dopamine (Nutt and Fellman, 1984). Reduction of the formation of 3-O-
methyldopa and enhancement of the bioavailability of L-dopa is, however, achieved by
specifically inhibiting COMT. Recently, two COMT inhibitors, entacapone and tolca-
pone, have been introduced to the market as adjuncts to the combination therapy (L-
dopa/DDC inhibitor) of Parkinson’s disease.
2.2. Conjugation of catechols
A catecholic structure, two adjacent hydroxyls in a phenol ring, is found in many
physiological compounds and in various drugs and drug candidates. Many catecholic
drugs (Table 1) mediate their effects via the same receptors as physiological catechols.
Consequently, catechol seems to be a central pharmacophore and will probably exist
also in future drugs, especially in those developed for psychiatric disorders and neuro-
logical illnesses. In addition to the compounds in Table 1, catechols with pharmacolog i-
cal activity include noradrenaline (adrenergic α- and β-receptor agonist), salsolinol 1-
carboxylic acid (naturally occurring amino acid), apomorphine (emetic, dopaminergic
receptor agonist), dihydrexidine and SKF 38393 (dopaminergic 1 receptor agonists),
rimiterol (adrenergic β2-receptor agonist), capsazepine (vanilloid receptor antagonist),
rosmarinic acid (anti-inflammatoric, C3-convertase inhibitor), tyrphostin (protein tyro-
sine kinase inhibitor) and catechin polyphenols (peroxynitrite scavengers). An impor-
tant group of catecholic compounds occurring in the body are the phase I metabolites of
catecholamines and estrogens.
The major metabolic routes of the clinically used catecholic drugs listed in Table 1
imply the central role of conjugation reactions in the deactivation and elimination of
them. The most relevant reactions are methylation, glucuronidation and sulphation, and
depending on the substrate and tissue one of them prevails. For example, the predomi-
nant conjugation pathway of catecholamines is methylation, although a considerable
amount of dopamine sulphate is formed in the gastrointestinal tract, while glucuronida-
tion seems to be of less importance (Boulton and Eisenhofer, 1998). Further, the DDC
inhibitors carbidopa and benserazide are mainly methylated, while the most important
elimination route of the COMT inhibitor entacapone is glucuronidation. Besides
physico-chemical features, the conjugation pattern of a catechol is affected by for in-
stance the administration route, interindividual variations and the relative capacity of
the enzymes involved. For example, glucuronidation is known for a high capacity and
thus often prevails over sulphation at high doses (Gibson and Skett, 1994).
8Table 1. Clinically used catecholic drugs in Finland 1999 and their major metabolism routes.
Name Pharmacological
action
Major
metabolism
routes
Adrenaline R4: CH(OH)CH2NHCH3 Adrenergic α- and β-
receptor agonist
Oxidation,
methylation
Benserazide R3: OH
R4: CH2NHNHCOCH(NH2)CH2OH
Dopadecarboxylase
inhibitor
Hydroxylation,
methylation
Carbidopa R4: CH2C(NHNH2)(CH3)COOH Dopadecarboxylase
inhibitor
Methylation
Dobutamine R4: (CH2)2NHCH(CH3)(CH2)2C6H4OH Adrenergic β1-receptor
agonist
Methylation
Dopamine R4: CH2CH2NH2 Adrenergic α-, β- and
dopaminergic receptor
agonist
Oxidation,
methylation
Dopexamine R4: (CH2)2NH(CH2)6NH(CH2)2C6H5 Adrenergic β2- and
dopaminergic receptor
agonist
Entacapone R3: NO2
R5: CH=C(CN)CON(CH2CH3)2
COMT inhibitor Glucuronidation
Isoprenaline R4: CH(OH)CH2NHCH(CH3)2 Adrenergic β1- and β2-
receptor agonist
Methylation
L-dopa R4: CH2CH(NH2)COOH Dopamine precursor Decarboxylation,
methylation
α-Methyldopa R4: CH2C(NH2)(CH3)COOH Antihypertensive with
central mechanism
Sulphation
Even though the nitrocatecholic COMT inhibitor tolcapone has been implicated in fatal
hepatotoxicity (e.g. Assal et al., 1998) and was withdrawn from the market in European
Union countries in 1998, its metabolism is interesting to compare with that of the
structurally related entacapone. Both COMT inhibitors are almost completely metabo-
lised before excretion in the urine and faeces (Wikberg et al., 1993, Jorga et al., 1999a).
Consequently, their short elimination half-lives (0.3 h for entacapone and 2.3 h for tol-
capone, Keränen et al., 1994, Dingemanse et al., 1995) may be partly due to extensive
metabolism. Interestingly, despite the structural similarities with entacapone, tolcapone
is eliminated at a 7-8 times lower rate. Over 95% of the urinary metabolites of entaca-
pone have been reported to represent glucuronides of entacapone and its (Z)-isomer,
whereas glucuronides of tolcapone account for 27% of the urinary metabolites (Wikberg
et al., 1993, Jorga et al., 1999a). In humans, no methylation of entacapone has been de-
tected, but minor amounts of 3-O-methyltolcapone have been found in plasma, urine
and faeces.
The conjugation of catechols is catalysed by various forms of COMTs, UGTs and
SULTs. Many of them have been cloned and expressed, and preliminary studies on their
substrate acceptance have been carried out. However, research into the factors deter-
mining their substrate selectivities towards catecholic compounds is still in its infancy,
and it is not possible to make predictions of the route and rate of conjugation from the
R6 R5
R4
R3HO
HO
9molecular structure. That would, however, be useful in assessing the capacity of cate-
cholic drug candidates for interactions with physiological catechols, and other cate-
cholic drugs, already at early stages of the drug development process.
2.1.1. Glucuronidation
A family of UDP-glucuronosyltransferases catalyses the conjugation of a nucleophilic
O-, N-, S-, or C-atom with UDP-glucuronic acid (UDPGA) usually resulting in a more
water-soluble glucuronide (Tephly and Burchell, 1990). The reaction mechanism is an
SN2-like nucleophilic substitution, in which the acceptor group attacks the C1 of the py-
ranose acid ring of UDPGA (Fig 1).
Fig. 1. Glucuronidation of catechol catalysed by UGT.
UGTs are bound to the endoplasmic reticulum, the substrate binding sites towards the
lumen. Today, at least 20 members of the human UGT family have been identified on
the basis of the amino acid sequences obtained from cDNAs and genomic clones
(Clarke, 1998). The high sequence similarity between the isoforms in the carboxytermi-
nal end seems to indicate the UDPGA binding site, while the more variable aminoter-
minal end probably determines the substrate specificity of the enzymes (Clarke and
Burchell, 1994). The isoforms can be divided into two subfamilies with the criterion of
greater than 60% sequence similarity within the subfamily (Burchell et al., 1995).
Members of the UGT1 gene family are designated as phenol- and bilirubin-metabolising
isoforms, and enzymes in the UGT2 family are known as steroid-metabolising isoforms.
However, overlapping substrate acceptance has been detected both within and between
the subfamilies making this classification sometimes inadequate. Because only few in
vitro studies on the glucuronidation of catecholic compounds other than catechol estro-
gens have been carried out, the contribution of different UGT isoforms to the glucu-
ronidation of this type of compound is exemplified with phenols (Table 2). A recom-
mended nomenclature based on evolutionary divergence is applied to the isoforms
(Mackenzie et al., 1997).
Even though almost all the isoforms shown in Table 2 accept both catechol estrogens
and other phenolic compounds, some of them play a quantitatively or qualitatively more
important role in the glucuronidation of these types of compounds. UGT1A1 is a clini-
cally relevant isoform catalysing the esterification of at least one of the two propionic
acid side chains of the toxic haem breakdown product bilirubin (Bosma et al., 1994).
Mutations in the UGT1 gene complex affecting all UGT1 enzymes cause potentially
lethal hyperbilirubinemia known as Griggler-Najjar syndrome type I (Clarke et al.,
1997). Griggler-Najjar syndrome type II is caused by less dramatic mutations or het-
erozygous expression of mutant and normal alleles. Gilbert’s syndrome, associated with
mutation in the promoter region of UGT1A1 exon, has been detected in about 6% of the
population (Miners and Mackenzie, 1991). In addition to the raised serum bilirubin co n-
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centrations, a decrease in the glucuronidation of for example acetaminophen has been
observed in people suffering from this syndrome (De Morais et al., 1992). In addition to
bilirubin, UGT1A1 catalyses the glucuronidation of catechol estrogens, phenols, an-
thraquinones and flavones with diverse structures (Senafi et al., 1994). Interestingly,
octylgallate, which has a pyrogallol structure, has appeared to be a better substrate of
UGT1A1 than bilirubin itself. The important function of UGT1A1 in eliminating biliru-
bin in conjunction with the wide substrate acceptance and genetic polymorphism may
imply possibilities for interactions between compounds glucuronidated via this isoform.
On the other hand, UGT1A1 is expressed at higher levels in the liver compared with the
other UGT1 isoforms and possibly exhibits a high capacity (Sutherland et al., 1992).
Table 2. Human UGT isoforms contributing to the metabolism of phenols and
catechol estrogens.
Isoform Major substrates Phenols Catechol
estrogens
Reference
UGT1A1 Bilirubin + + Senafi et al., 1994
UGT1A3 Scopoletin,
norbuprenorphine
+ + Mojarrabi et al., 1996
Green et al., 1998
Cheng et al., 1998a
UGT1A4 Amines + - Green and Tephly, 1996
UGT1A6 Planar phenols + - Harding et al., 1988
Ebner and Burchell, 1993
Wooster et al., 1993
UGT1A7a Bulky phenols + + Strassburg et al., 1998
UGT1A8a Phenolic compounds + + Mojarrabi and Mackenzie, 1998,
Cheng et al., 1998b
UGT1A9 Bulky phenols + + Ebner and Burchell, 1993
Wooster et al., 1993
UGT1A10a Phenolic compounds + + Mojarrabi and Mackenzie, 1998,
Strassburg et al., 1998
UGT2A1 Phenolic compounds + + Jedlitschky et al., 1999
UGT2B4 Hyodeoxycholic acid,
catechol estrogens
+ + Ritter et al., 1992
UGT2B7 3,4-Catechol estrogens,
hyodeoxycholic acid,
carboxylic acid drugs
+ + Ritter et al., 1990
Ritter et al., 1992
Jin et al., 1993a
UGT2B8 Estriol + ? Irshaid and Tephly, 1987
Coffman et al., 1990
UGT2B11 Phenolic compounds + + Jin et al., 1993b
UGT2B15 Dihydrotestosterone + + Chen et al., 1993
Green et al., 1994
UGT2B17 Dihydrotestosterone + ? Beaulieu et al., 1996
aNot expressed in the liver
The main isoforms specialised in the glucuronidation of phenols are UGT1A6 and
UGT1A9. Screening of over 100 compounds confirmed the earlier findings with the rat
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orthologue (Jackson et al., 1988) showing that UGT1A6 preferentially catalyses the
glucuronidation of small, planar phenols (Ebner and Burchell, 1993). In contrast,
UGT1A9 was found to accept nonplanar phenols and anthraquinones, flavones, alco-
hols, aromatic carboxylic acids, steroids and drugs with diverse structures (e.g. propo-
fol, propranolol, diflunisal, ethinylestradiol, furosemide, ibuprofen, ketoprofen and na-
proxen). There is evidence of polymorphism in UGT1A6; the genotype that contains
two mutations exhibits a lowered activity towards 3-O-methyldopa, methylsalicylate
and some β-blockers in vitro, but the clinical relevance of the polymorphism remains
unclear (Ciotti et al., 1997). UGT1A9 may be the key enzyme in the detoxification of
xenobiotics, since no special endogenous substrate, such as bilirubin for UGT1A1, has
been identified and it shows substrate acceptance wider than any other UGT isoform.
The importance of UGT1A7, UGT1A8, and UGT1A10, predominantly expressed in the
gastrointestinal tract rather than in the liver, is still unclear, but their tissue localisation
may refer to a special function in the metabolism of xenobiotics (Mojarrabi and
Mackenzie, 1998). UGT1A4, the major isoform catalysing N-glucuronide formation, is
suggested to have a minor role in the glucuronidation of phenolic hydroxyls (Green and
Tephly, 1996). The recently cloned and characterised UGT2A1 appeared to be specific
for olfactory tissue and catalyses the inactivation of odorants (Jedlitschky et al., 1999).
The major isoforms catalysing the glucuronidation of catechol estrogens are
UGT2B7 and UGT1A1. UGT2B7 has shown a 100-, 30- to 90-, and 2- to 100-fold effi-
ciency towards catechol estrogens compared with UGT2B4 (Ritter et al., 1992, Kim et
al., 1997), UGT2B11 (Jin et al., 1993b) and UGT2B15 (Tephly et al., 1998), respec-
tively. However, the activity is much higher towards 4-hydroxyestrogenic than 2-
hydroxyestrogenic catechols. This is in contrast to UGT1A1, which shows high activity
towards 2-hydroxyestrogens (Tephly et al., 1998). In theory, catecholamines may be
endogenous inhibitors of the metabolism of catechol estrogens. However, the inability
of noradrenaline to inhibit UGT1A1-, UGT1A3-, or UGT2B7-catalysed glucuronidation
of catechol estrogens suggests that catecholamines are unlikely to interfere with their
glucuronidation (Cheng et al., 1998a). UGT2B7 is a clinically important isoform, since
in addition to catechol estrogens, it catalyses the glucuronidation of many drugs in-
cluding NSAIDs and morphine (Jin et al., 1993a, Coffman et al., 1997). The wide sub-
strate acceptance (Green et al., 1994) and wide expression in many tissues (Levesque et
al., 1997) of UGT2B15 suggest that also this isoform may exhibit a high contribution to
the glucuronidation pathway. The significance of the polymorphic expression reported
for UGT2B4 (Levesque et al., 1999), UGT2B7 (Coffman et al., 1998), and UGT2B15
(Levesque et al., 1997) remains to be determined.
In human liver microsomes both electron-donating and electron-withdrawing para-
substituents have been shown to enhance the glucuronidation of phenols, whereas bulky
ortho-substituents inhibit the reaction (Temellini et al., 1991). These general observa-
tions represent the sum effect of all contributing isoforms, yet basic knowledge of the
substrate acceptance of the isoforms suggests that the various forms may obey very dif-
ferent rules. Despite the availability of recombinant enzymes, no systematic structure-
activity analysis, that would take into account various substituent effects, has been car-
ried out for any of the isoforms. The mechanisms of catalysis and the contributing
amino acids have been investigated by chemical modification of UGT1A6 (Battaglia et
al., 1994a, 1994b) and site-directed mutagenesis of UGT1A1 and UGT2B17 (Ciotti and
Owens, 1996, Ciotti et al., 1998, Dubois et al., 1999). However, since the three-
dimensional structures are not known, models of the active sites remain inaccurate.
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2.2.2 Methylation
COMT catalyses the transfer of a methyl group from S-adenosyl-L-methionine
(AdoMet) to one of the catecholic hydroxyls (Männistö et al., 1992) (Fig. 2). COMT
accepts a wide range of structurally variable substrates with the only strict requirement
that the substrate must have a catechol structure (Guldberg and Marsden, 1975).
Fig. 2. Methyl transfer from AdoMet to catechol in the COMT-catalysed reaction.
COMT exists in two forms; the soluble form (S-COMT) is located in cytosol and the
membrane-bound form (MB-COMT) is attached to the rough endoplasmic reticulum
(Tilgmann and Kalkkinen, 1991, Bertocci et al., 1991, Lundström et al., 1991, Ulmanen
et al., 1997). The amino acid sequences of the two forms differ only by a 50-amino-
acid-long extension in the MB-form, which is believed to represent the membrane an-
choring signal sequence (Ulmanen and Lundström, 1991). Due to the structural simi-
larities the two forms are thought to catalyse the methylation reaction with the same
mechanism. The human brain MB-COMT is, however, reported to exhibit approxi-
mately 100 times lower K
m
 value for dopamine than the soluble form of the enzyme
(Rivett and Roth, 1982, Nissinen, 1984). Studies with cloned and expressed COMT
forms have confirmed the existing kinetic differences between the two forms (Malherbe
et al., 1992, Lotta et al., 1995). They also show different regioselectivity towards cate-
cholic hydroxyls in vitro (Nissinen, 1984, Lotta et al., 1995). S-COMT is the predomi-
nant form in most tissues, but a Western blot analysis of the distribution of COMT has
revealed that MB-COMT predominates in the human brain (Tenhunen et al., 1994).
This along with the higher affinity of catecholamines to MB-COMT at physiological
concentrations indicate that MB-COMT may be more relevant in the termination of
catecholaminergic neurotransmission, while S-COMT is likely to play a more important
role in the inactivation of endogenous and xenobiotic catechols in other tissues (Roth,
1992, Lotta et al., 1995, Bonifati and Meco, 1998).
In the 1980s COMT was discovered as a potential drug target. Peripheral COMT in-
hibition was desired in order to increase the bioavailability of L-dopa in the combina-
tion therapy (L-dopa/DDC inhibitor) of Parkinson’s disease. Search for potent and se-
lective inhibitors lead to the purification of S-COMT from rat liver (Tilgmann and
Kalkkinen, 1990) and human placenta (Tilgmann and Kalkkinen, 1991) and subsequent
cDNA cloning (Salminen et al., 1990, Lundström et al., 1991). MB-COMT was cloned
from the human hepatoma cell line G2 (Bertocci et al, 1991). Recombinant COMT
proteins have been produced in Escherichia coli (Lundström et al, 1992, Malherbe et
al., 1992), in mammalian cell lines (Lundström et al., 1991, Bertocci et al., 1991, Mal-
herbe et al., 1992, Tilgmann et al., 1992) and in baculovirus-infected insect cells
(Tilgmann et al., 1992).
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Advances in molecular biology have provided tools not only for studies on the structure,
subcellular localisation, and tissue distribution of the COMT proteins and genes encod-
ing them, but also for investigations on the mechanism of the COMT-catalysed reaction.
Great progress in the field was made when Vidgren et al. succeeded in resolving the
crystal structure of rat S-COMT (1994). The amino acid sequences of rat and human S-
COMT exhibit 81% homology, and especially the active site is highly conserved (Vid-
gren and Ovaska, 1997). The active site consists of the AdoMet binding site and the
catalytic site. The catalytic catechol-binding site is in a shallow groove on the surface of
the protein (Fig. 3). Magnesium ion is essential for the catalytic activity. It is coordi-
nated to a water molecule, to the side chain oxygens of three amino acid residues
(Asp141, Asp169, Asn170) and to both of the catechol hydroxyls. Magnesium ion sig-
nificantly lowers the pK
a
 of the catechol hydroxyls thereby making them more easily
ionised. However, the negatively charged carboxyl acid group of Glu199 located a hy-
drogen bond from one of the hydroxyls stabilises the unionised form of this hydroxyl.
The other hydroxyl donates the proton to the amino group of Lys144, and the ionised
hydroxyl attacks the electron-deficient methyl group of AdoMet leading to the methyl
transfer to the catechol hydroxyl. Lys144 acts as a catalytical base in this SN2-like nu-
cleophilic substitution reaction. Hydrophobic amino acids surrounding the catalytic site
(especially Trp38 and Pro174) define the substrate selectivity of the enzyme towards
different side chains of catecholic compounds.
Fig 3. A stereoview of the catechol binding site adopted from the crystal structure of rat S-
COMT (Vidgren et al., 1994). Bound AdoMet is shown left and magnesium complexed with two
hydroxyls of pyrogallol in the middle.
After early conflicting results on the kinetic mechanism of COMT that suggested a
rapid-equilibrium random-order mechanism (Flohe and Schawabe, 1970, Coward et al.,
1973) and a ping-pong mechanism (Borchardt, 1973), Woodard et al. (1980) showed
that the methylation reaction proceeds through an SN2-like transition state. Subsequently
a sequentially ordered mechanism was established (Rivett and Roth, 1982, Tunnicliff
and Ngo, 1983). Lotta et al. (1995) demonstrated the following binding and dissociation
order: AdoMet, magnesium, catechol substrate and methylated catechol product, mag-
nesium and demethylated AdoMet (AdoHcy). The previously proposed order suggest-
ing magnesium ions to bind first to the free enzyme in a rapid equilibrium reaction
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(Jeffery and Roth, 1987) could be argued on the basis of the crystal structure of COMT;
the AdoMet binding site is located behind the magnesium binding site thereby forcing
AdoMet to bind before magnesium. Catecholamines are predominantly methylated at
the meta-position, which in early studies was suggested to be due to the polar ionic side
chain favouring that binding orientation (Creveling et al., 1970, 1972). This interpreta-
tion was later verified by computer-aided modelling of one low-activity conformer of
dopamine to the active site of COMT (Lotta et al., 1995). Modelling revealed that, in
deed, binding in the orientation leading to para-methylation causes more unfavourable
interactions with the hydrophobic residues surrounding the active site compared with
the other binding mode. This might not, however, be the only explanation, because only
one low-energy conformer was studied and the flexible side chain may adopt variable
orientations. In addition to the hydrophobic interactions, the nature of substituents at
various positions may affect the regioselectivity with other mechanisms as well. For e x-
ample, in ring-fluorinated catecholamines variable preference to the hydroxyls has been
explained by changes in nucleophilicity (Firnau et al., 1981, Creveling et al., 1981,
Thakker et al., 1986).
COMT is usually thought to possess a very wide acceptance of structurally diverse
catecholic compounds. The clinical importance of COMT inhibition has directed studies
on the structure-activity relationships to the factors affecting inhibition potency rather
than to the methylation reaction itself. Two research groups, both of which would intro-
duce its own molecule to clinical use later, independently synthesised potent and selec-
tive COMT inhibitors with 3-nitrocatechol as the key structure (Borgulya et al., 1989,
Bäckström et al., 1989). Further studies showed that inhibition activity is enhanced by
electron-withdrawing substituents at positions 3 and 5 and that binding affinity is im-
proved by a hydrophobic substituent at position 5 (Taskinen et al., 1989, Lotta et al.,
1992). Compounds containing electronegative groups, such as 3,5-dinitrocatechol, de-
crease the nucleophilicity of the ionised catechol hydroxyls and strongly stabilise the
ionised catechol-COMT complex thus making the energy barrier for the methylation
high (Vidgren and Ovaska, 1997, Ovaska and Yliniemelä, 1998). The few studies on the
substrate selectivity of COMT have emphasised the relevance of hydrophobicity in the
increment of affinity (Raxworthy and Gulliver, 1982, Youde et al., 1984). However,
these conclusions have been derived on the basis of a small number of related com-
pounds rather than a proper structure-activity analysis.
Existence of polymorphic COMT forms, a thermolabile low activity and a thermo-
stabile high activity COMT, has been reported (Scanlon et al., 1979, Weinshilboum,
1984, 1988, Boudiková et al, 1990, Grossman et al., 1992). The molecular basis of the
polymorphism is variation at the 108 amino acid residue (Val-108 being thermostabile
and Met-108 thermolabile) (Lotta et al., 1995). The two alleles result in homozygous
individuals with high or low COMT activity and heterozygous individuals with inter-
mediate activity (Bonfati and Meco, 1999). A markedly higher frequency of the high
activity allele has been reported among Chinese and Japanese people (~75%) than
among Caucasians (50%) (Xie et al., 1997, Kunugi et al., 1997). Previous studies have
also shown that Orientals and black Americans exhibit a higher COMT activity than do
Caucasians (Rivera-Calimlim and Reilly, 1984, McLeod et al., 1994). In contrast, a
lower COMT activity has been reported among the Saami population (Klemetsdal et al.,
1994). Several studies have suggested the association of COMT polymorphism with
neurological and psychiatric disorders (e.g. Kunugi et al., 1997, Strous et al., 1997a,
Chen et al., 1997, Lachman et al., 1996) and with breast cancer risk (Lavigne et al.,
1997, Thompson et al., 1998), but also contradicting findings have been published (e.g.
Xie et al., 1997, Strous et al., 1997b, Ohara et al., 1998, Millikan et al., 1998).
15
2.2.3. Sulphation
The conjugation of 3’-phosphoadenosine 5’-phosphosulphate with an O-, N- or S- ac-
ceptor group is catalysed by cytosolic sulphotransferases. The SULT enzyme family
includes enzymes that catalyse the sulphation of phenolic xenobiotics (P-PST), cate-
cholamines (M-PST), estrogens (EST), and steroids (HST) (Coughtrie, 1998). Different
isoforms exhibit overlapping substrate specificities, although many of them show pref-
erence towards some type of substrates. Structure-activity relationships have not been
fully investigated for any of the isoforms. However, in human liver samples neutral sub-
stituents, usually rather in the ortho- than in the para-position, have been found to fa-
vour phenol sulphation (Temellini et al., 1991). SULT1A3 (M-PST), which is responsi-
ble for the sulphation of catecholamines, is predominantly expressed in the small intes-
tinal mucosa and may have a special role in the detoxification of dietary xenobiotics
(Coughtrie, 1998). As a result of the action of SULT1A3, circulating catecholamines
appear mostly as sulphate conjugates thus facilitating their transportation to other tis-
sues. At least SULT1A1 (P-PST) is genetically polymorphic, but further investigations
on its significance are needed (Coughtrie et al., 1999).
2.3. In vitro studies on catechol conjugation
In vitro studies on conjugation reactions are usually performed by incubating the stud-
ied compound, in the presence of a cosubstrate, with the enzyme and by measuring the
reaction velocity. The most common enzyme sources from different species are tissue
homogenates, subcellular fractions and recombinant enzymes. Since following the dis-
appearance of the substrate is insensitive and unspecific, reaction velocity is normally
determined on the basis of formation of the products. In kinetic studies, the initial reac-
tion velocity is determined as a function of substrate concentration at the saturating con-
centration of the cosubstrate (Cornish-Bowden, 1995). Most enzymes follow Michaelis-
Menten kinetics; reaction velocity increases almost linearly at low substrate concentra-
tions after which it starts to reach the maximum asymptotically. The enzyme kinetic pa-
rameters V
max
 and K
m
, describing the capacity of the reaction and the affinity of the sub-
strate to the enzyme, are derived by fitting the Michaelis-Menten equation (1) to the
initial velocity values obtained. At low substrate concentrations, normally occurring in
vivo, the reaction is best described by the ratio of V
max 
and
 
K
m
.
 (1) V = (V
max
 x [s]) / (K
m
 + [s])
V = reaction velocity
V
max
 = maximum reaction velocity
[s]   = substrate concentration
K
m
 = substrate concentration at half the maximum velocity
In addition to studies on substrate selectivity and reaction mechanisms, in vitro methods
may be utilised in the selection of the animal model for toxicity studies and in the early
assessment of metabolism and metabolic interactions in humans. Attempts to predict in
vivo clearance based on in vitro data have been made almost exclusively utilising com-
pounds that are metabolised by phase I enzymes (Houston and Carlile, 1997). However,
a study on tolcapone shows that reasonably accurate predictions are possible also for
compounds metabolised mainly by phase II enzymes (Lave et al., 1996).
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2.3.1. UGT assays
The major difficulty of in vitro studies on UGT is its latency, due to its subcellular lo-
calisation in the rough endoplasmic reticulum, the active site towards the lumen. Activ-
ity may be enhanced by damaging the membrane by detergents or sonication, which
improves the access of the substrates to the active site. Optimum concentrations of de-
tergents (e.g. digitonin, Lubrol WX, Brij 58, CHAPS, Tergitol NP-10 and Triton X-100)
have been shown to increase the UGT activity by 2- to 5-fold (Winsnes, 1969, Mag-
dalou et al., 1979, Thomassin et al., 1985, Lawrence et al., 1992, Lett et al., 1992, Mar-
tin and Black, 1994). However, detergents have been reported to alter not only the V
max
but also the K
m
 values (Thomassin et al., 1985) and excessive detergent concentrations
deactivate the enzyme. There is no direct evidence of the contribution of Mg2+ ion to the
glucuronidation reaction, although magnesium has been found to increase the glucu-
ronidation rate of for example morphine (Lawrence et al., 1992). β-Glucuronidase,
which is located in the lumen of endoplasmic reticulum, as are UGTs, catalyses the hy-
drolysis of glucuronides, but it can be selectively inhibited by saccharolactone. In addi-
tion, the pH normally used in the glucuronidation studies (6-8) does not favour the ac-
tion of β-glucuronidase that exhibits a pH optimum at 4-5 (Kauffman, 1994).
Assays for UGT include spectrometric and fluorometric methods, for instance con-
tinuous fluorometric monitoring of reaction products (Väisänen et al., 1983), but mostly
common chromatographic techniques have been utilised. Most methods have been de-
veloped for specific substrates. However, a very widely used method, introduced by
Bansal and Gessner (1980), is suited for structurally diverse compounds including sim-
ple phenols and hormones. The universality of the method is based on uridine diphos-
pho[U-14C]glucuronic acid (14C-UDPGA) that is conjugated with the acceptor substrates
forming 14C-labelled products, which makes authentic reference standards unnecessary.
In this method, the formed glucuronides are separated from unreacted UDPGA on
preparative silica gel TLC plates with a mixture of n-butanol, water, acetone, glacial
acetic acid and 30% ammonia (70:60:50:18:1.5). The glucuronide spots are identified
by autoradiography and quantitated by liquid scintillation counting after scraping from
the plate. The method with minor modifications has been especially useful in studies on
substrate selectivity of UGTs. The tedious and time-consuming autoradiography and
scraping with subsequent liquid scintillation counting have been replaced by quantita-
tion of the radioactive glucuronides directly from the TLC plates by a digital autoradio-
graph or a radioanalytical imaging system (Ritter et al., 1990, Ebner and Burchell,
1993). The main disadvantage of the method is its inability to separate multiple glucu-
ronides originating from the same parent compound. Therefore a general HPLC method,
based on 14C-UDPGA and on-line radioactivity detection (Coughtrie et al., 1986), re-
cently published in an improved form (Ethell et al., 1998), may overcome the old TLC
assay.
2.3.2. COMT assays
As explained previously, Mg2+ ions are essential for the COMT-catalysed methylation
reaction. Some other divalent cations, such as Cd2+, Hg2+, Mn2+ and Cu2+, have been
found to promote methylation as well (Axelrod and Tomchick, 1958, Senoh et al., 1962,
Flohe 1974, Boadi et al., 1991). In contrast, Ca2+ ions seem to inhibit COMT (Weinshil-
boum and Raymond, 1976). Purified human S-COMT has been shown to require cys-
teine as a reducing agent to maintain its activity (Tilgmann and Kalkkinen, 1991). Other
agents capable of inhibiting the deactivation, probably caused by oxidation of the sul-
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phydryl groups of the protein, include mercaptoethanol and dithiothreitol (Tilgmann
and Ulmanen, 1996). Reducing agents in the reaction mixture may also protect the cate-
cholic hydroxyls from oxidation during the reaction. AdoHcy, the demethylated end
product of AdoMet, has been found to inhibit COMT (Coward et al., 1973), but at low
substrate and enzyme and saturating AdoMet concentrations its effect becomes negligi-
ble.
Many early COMT assays relied on fluorometric (e.g. Axelrod and Tomchick, 1958),
spectrophotometric (e.g. Coward and Wu, 1973, Borchardt, 1974) or most commonly
radiochemical methods (e.g. Jonas and Gershon, 1974, Raymond and Weinshilboum,
1975, Gulliver and Tipton, 1978, Bates et al., 1979, Zürcher and Da Prada, 1982).
Adding a radioactively labelled substrate or cosubstrate (S-adenosyl-L-[methyl-
14C]methionine or S-adenosyl-L-[methyl-3H]methionine) to the reaction mixture resulted
in radioactive end products that could be separated from the parent compounds by liq-
uid-liquid extraction or thin-layer chromatography, and that could be subsequently
quantitated in a liquid scintillation counter. Radiochemical methods are simple and sen-
sitive, applicable for various catechol substrates and require no reference standards.
However, impurities in radiochemicals and variable recovery in the extraction proce-
dure impair their reliability. In addition, regioisomeric O-methylated metabolites, pro-
duced from many compounds in vitro, cannot be quantitated separately. Development of
gas chromatographic (Creveling et al., 1972, Lin and Narasimhachari, 1974, Koh et al.,
1991) and liquid chromatographic COMT assays has, however, enabled separation of
the regioisomeric products. High-performance liquid chromatography has been coupled
with various detection devices including UV (Pennings and Van Kempen, 1979), elec-
trochemical (Borchardt et al., 1978, Shoup et al., 1980, Koh et al., 1981, Nissinen and
Männistö, 1984), fluorometric (Zaitsu et al., 1981, Nohta et al., 1984, Smit et al., 1990,
Zürcher et al., 1996) and radiochemical detectors (Nissinen, 1985). Most of the assays
are intended for the measurement of COMT activity in different tissues including those
with a low level of COMT expression, such as brain or erythrocytes. Especially assays
utilising electrochemical, radioactivity and fluorescence detectors are specific and sen-
sitive (respective limits of detection 0.5, 0.04 pmol and 11 fmol reaction product per
injection) (Reenilä et al., 1995, Tuomainen et al., 1996, Nissinen, 1985, Zürcher et al.,
1996). These methods use a specific substrate and do not allow determination of COMT
activity towards catechols with diverse structures.
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3. Aims of the study
The primary aims of this study were 1) to evaluate the susceptibility of nitrocatecholic
COMT inhibitors to glucuronidation in vitro and 2) to characterise the structural fea-
tures of catecholic compounds that determine their properties as S-COMT substrates.
The specific aims were:
to develop and validate analytical methods for the in vitro studies on the glucuronida-
tion and methylation of catechols
to evaluate the glucuronidation of various nitrocatechols in rat liver microsomes
to characterise the human UGT isoforms that are mainly responsible for the glucu-
ronidation of the COMT inhibitors entacapone and tolcapone
to compare the glucuronidation kinetics of entacapone and tolcapone in rat and human
liver microsomes as well as by human UGT isoforms
to compare the substrate selectivity of rat and human S-COMT
to construct predictive models for the methylation of catechols by human S-COMT
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4. Materials and methods
The original publications contain more detailed descriptions of the materials and meth-
ods utilised.
4.1. Chemicals
Most of the 57 catecholic compounds were purchased from commercial sources and
were of the highest grade available. Nitrocatechol derivatives 3-nitrocatechol, 3,5-
dinitrocatechol, entacapone, entacapone(Z)-isomer, nitecapone and tolcapone were
kindly supplied by Orion Pharma (Espoo, Finland). UDPGA was obtained from Sigma
Chemical Company (St. Louis, Missouri, USA) or Boehringer-Mannheim (Mannheim,
Germany), AdoMet from Boehringer-Mannheim and 14C-UDPGA and 14C-AdoMet from
NEN Du Pont (Boston, USA). 4-Nitrophenyl-β-D-glucuronide (4NPG) was purchased
from Sigma Chemical Company and vanillic acid from Aldrich (Sigma-Aldrich
Chemie, Steinheim, Germany). Reference standards of the 3-O-glucuronides of entaca-
pone and tolcapone were synthesised at the Department of Pharmaceutical Chemistry,
University of Helsinki, Finland (Luukkanen et al., 1999).
4.2. Enzyme sources
Rat liver microsomes were prepared from liver homogenates of male Wistar rats by dif-
ferential centrifugation at the Finnish Institute of Occupational Health, Helsinki (I, II).
The rats were pre-treated with creosote (200 mg in 4 ml olive oil/kg) or did not receive
any pre-treatment. Protein concentrations of the microsomal suspensions were deter-
mined by the method of Lowry et al. (1951). Human liver microsomes were purchased
from Human Biologics Inc. (Arizona, USA) (III). Microsomes were stored at -70oC be-
fore being used.
Recombinant V79 cell lines expressing human UGT isoforms were grown up and
maintained at the Department of Molecular and Cellular Pathology, Ninewells Hospital
and Medical School, Dundee, Scotland, as described previously (Ethell et al, 1998)
(III). The harvested cells were stored at -70oC and, before use, disrupted by sonication.
The protein concentrations were determined using bovine serum albumin as a standard
(Lowry et al., 1951). Recombinant rat and human S-COMT proteins were produced in
E. coli at the Department of Molecular Biology and Target Protein Research, Orion
Pharma, Finland, as described in detail earlier (Lundström et al., 1992) (IV, V). The
harvested cells were disrupted by sonication and kept at -70oC before being used for the
enzyme assays. The total protein concentrations of the lysates were determined accord-
ing to Bradford (1976).
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4.3. Reaction mixtures
In the UGT assays the reaction mixture contained MgCl2 (5 mM), UDPGA (2-5 mM),
substrate (0.010-2.5 mM), and the UGT source (microsomes or lysates from cells ex-
pressing UGT isoforms) in 50-100 mM phosphate or Tris/maleate buffer (pH 7.4) (I-
III). When radioactivity was utilised in the quantitation, 0.1 µCi 14C-UDPGA was added
to the reaction mixture (II, III). The samples were incubated at 37°C for 15-60 minutes
before the reactions were terminated by adding organic solvent (methanol or acetoni-
trile) or 4 M perchloric acid. The precipitated proteins were removed by centrifugation.
The COMT assays were performed in 100 mM Na2HPO4/NaH2PO4 buffer (pH 7.4)
containing MgCl2 (5 mM), L-cysteine (20 mM), AdoMet (150 µM), 14C-AdoMet (0.1
µCi), a catechol substrate (0.25-3000 µM) and human or rat S-COMT bacterial lysate
(IV, V). In kinetic studies, the amount of enzyme was chosen separately for each sub-
strate on the basis of the concentration range used in order to maintain appropriate con-
ditions for Michaelis-Menten kinetics. The samples were pre-incubated at 37oC for 5
min before the reactions were started by adding the catechol substrate or the
AdoMet/14C-AdoMet mixture. After the 15- to 30-min-long incubation period the reac-
tions were terminated by adding cold 4 M perchloric acid. The samples were centri-
fuged before the HPLC analysis.
4.4. Analytical methods
4.4.1. Thin-layer chromatography (I-II)
The glucuronides of nitrocatechols were separated from the parent compounds and
UDPGA on RP-18 HPTLC plates using a horizontal development mode. The eluent
consisted of 50 mM NaH2PO4 (pH 2.2) and acetonitrile (6:4 v/v). The sample applica-
tion was performed utilising the Linomat IV spray-on technique (Camag, Muttenz,
Switzerland). The glucuronides were quantitated with the aid of one sample in which
14C-UDPGA had been added before incubation. Four different volumes of this sample
were applied to the plate in order to obtain a calibration curve. After development, the
air-dried plates were scanned with a Camag TLC Scanner II, controlled by the Camag
Cats program version 3.17, at wavelengths specific for each nitrocatechol. Three of the
radioactivity-containing glucuronide spots were scraped from the plates and, after addi-
tion of liquid scintillation cocktail (Optiphase Hisafe 2, FSA Laboratory Supplies,
Loughborough, UK), quantitated in a liquid scintillation counter (Wallac 1410, Turku,
Finland). The amounts of the glucuronides in the standard spots, calculated from the
mean value derived from the radioactivity measurements, were fed into the Cats pro-
gram and the glucuronides in the other samples were quantitated on the basis of the den-
sitometric analysis.
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4.4.2. High-performance liquid chromatography
(II-V)
The UGT assays were performed according to published HPLC methods or by making
minor modifications to them (Ethell et al., 1998, Wikberg et al., 1993). The fluoromet-
ric COMT assay with 6,7-dihydroxycoumarin as the substrate was previously developed
at the Department of Pharmaceutical Chemistry, University of Helsinki, Finland
(Nummila, 1999), while the radiochemical assay for the determination of COMT activ-
ity towards various substrates (IV) was developed during this study. The experimental
conditions of the five HPLC methods utilised are summarised in Table 3.
Table 3. Chromatographic conditions of the HPLC methods utilised in the UGT and COMT as-
says. The mobile phase flow rate was 1.0 ml/min in all methods.
UGT/
COMT
HPLC
equipment
Column Oven
oC
Mobile phase
composition
Detection
UGT
(II)
1090,
Hewlett-Packard,
Waldbronn,
Germany
RP-18, LiChrosorb,
125 x 4 mm, 5 µm
(Hibar, Merck,
Darmstadt,
Germany)
35 25 mM NaH2PO4
(pH 2.2),
acetonitrile
(7:3a, 6:4b, v/v)
UV
(PU4020, Pye Uni-
cam)
305 nma, 278 nmb
UGT
(III)
Schimadzu
(LC-6A pumps),
Kyoto, Japan
Techspere ODS2,
250 x 46 mm, 5 µm
(HPLC Technology,
Macclesfield, UK)
- Binary gradient:
0-100% acetonitrile
in 0.05 M ammoni-
umacetate in 15 min
Radioactivityc,
(9701, Reeve Ana-
lytical, Glasgow,
Scotland)
UGT
(III)
1100,
Hewlett-Packard,
Waldbronn,
Germany
Hypersil BDS-C18,
250 x 4 mm, 5 µm
(Hewlett-Packard,
Waldbronn,
Germany)
40 25 mM NaH2PO4,
10 mM citric acid
(pH 2.2), methanol
(52:48a, 42:58b,
v/v)
UV,
(Hewlett-Packard,
Waldbronn,
Germany)
305 nma, 278 nmb
COMT
(IV, V)
1090,
Hewlett-Packard,
Waldbronn,
Germany
RP-18, LiChrosorb
(Hibar, Merck) and
Hypersil BDS-C18,
125 x 4 mm, 5 µm
(Hewlett-Packard)
40 50 mM Na2HPO4,
20 mM citric acid,
0.15 mM Na2-
EDTA (pH 3.2)d,
3-60% methanol
Radioactivitye,
(150TR, Packard,
Meriden, CT, USA)
COMT
(V)
1100,
Hewlett-Packard
Waldbronn,
Germany
Hypersil BDS-C18,
250 x 4 mm, 5 µm
(Hewlett-Packard
Waldbronn,
Germany)
40 50 mM Na2HPO4
(pH 3.0), methanol
(27:73 v/v)
Fluorescence,
(Shimadzu RF-535,
Kyoto, Japan)
excitation 335 nm,
emission 455 nm
afor entacapone
bfor tolcapone
c
a 200-µl cell with cerium-activated lithium glass as scintillant (Reeve Analytical)
d1.25 mM 1-octanesulphonic acid was added when basic substrates were analysed
e
a 300-µl cell with cerium-activated lithium glass as scintillant (Packard) or a 500-µl cell receiving scin-
tillation liquid (Monoflow 3, National Diagnostics, Atlanta, USA) 3 ml/min
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4.4.3. Method validation
The HPTLC method applied in the investigation of the glucuronidation of nitrocate-
chols by rat liver microsomes was validated with 4-nitrophenol as the model substrate
(I). The validation procedure comprised specificity, limit of quantitation, repeatability
of sample application (n=7), recovery (3 concentrations, n=6), reproducibility of the
method (6 concentrations, n=6), and reproducibility of the determination of the enzyme
kinetic parameters (n=6). The reliability of quantitation based on the method combining
densitometry and radioactivity measurement was tested by comparing the results ob-
tained from the same samples by this method and by the densitometric method that
utilises 4NPG as the reference standard (6 concentrations).
3,4-Dihydroxybenzoic acid (DHBA) was used as the model substrate in the valida-
tion of the new radiochemical HPLC method developed for the assay of COMT activity
towards various substrates (IV). In this method the methylated products were quanti-
tated by comparing their peak areas in the radioactivity detector with the total area of
radioactive peaks. The accuracy of this quantitation method was investigated by ana-
lysing samples containing different initial concentrations of DHBA simultaneously by
radioactivity and UV detection. In the UV detection, the 3-O-methylated product of
DHBA, vanillic acid, was used as the reference standard. Recovery was determined by
comparing the sum of AdoMet, vanillic and isovanillic acid peak areas in the radioac-
tivity detector with the peak area of unincubated AdoMet (n=6). The limit of quantita-
tion and the limit of detection were estimated for vanillic acid by using the criteria for
signal to noise ratio of ten and three. The same samples containing six initial concentra-
tions of DHBA (n=6) were used for investigating the reproducibility of the method and
the reproducibility of the determination of the enzyme kinetic parameters.
4.5. Enzyme kinetic analysis (I-V)
The apparent enzyme kinetic parameters V
max
 and K
m
 were determined by measuring the
initial reaction velocity as a function of catechol concentration at fixed cosubstrate con-
centration. The Michaelis-Menten equation was fitted to the initial velocity values using
the Leonora Steady-state Enzyme Kinetics program version 1.0 by A. Cornish-Bowden
(1994). In some cases equations for substrate inhibition and competitive or mixed inhi-
bition were used.
4.6. QSAR and molecular modelling (V)
The octanol-water distribution coefficients were calculated using the LOGKOW method
(Meylan and Howard, 1995), and the SPSS 8.0.1 program (SPSS Inc., Chicago, IL,
USA) was utilised in statistical analyses. The catechols were modelled by the Spartan
5.0 program (Wavefunction Inc., Irvine, CA, USA) and optimised by using the semiem-
pirical AM1 method. The molecular electrostatic potentials (MEP) were computed by
single point ab initio calculations at the 3-21G(*) level. The Insight II program (Mo-
lecular Simulations Inc., San Diego, CA, USA) was utilised in superimposing the cate-
chols on 3,5-dinitrocatechol in the active site model of rat S-COMT (Brookhaven Pro-
tein Data Bank entry 1VID).
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5. Results and discussion
5.1. Development and validation of enzyme
assays
5.1.1. Thin-layer chromatographic UGT assay for the determi-
nation of nitrocatechol glucuronidation (I, II)
An HPTLC method was developed for the assay of UGT activity towards nitrocate-
cholic compounds using 4-nitrophenol as the substrate. This compound is a generally
used, structurally relevant UGT substrate and the respective glucuronide, 4NPG, is
commercially available. 4NPG could be separated from the parent compound and from
UDPGA on RP-18 HPTLC plates with a mixture of 50 mM NaH2PO4 (pH 2.2) and
acetonitrile (6/4, v/v). The same chromatographic conditions were shown to be applica-
ble for the analysis of certain nitrocatechols as well (Fig. 4). All glucuronides were well
separated from the respective parent compounds and UDPGA. Good separation from
UDPGA was especially important in the analyses where radioactive spots were scraped
from the plate.
Fig. 4. Separation of glucuronides from parent compounds and UDPGA on RP-18 HPTLC
plates developed with 50 mM NaH2PO4 (pH 2.2) / acetonitrile (6/4, v/v) to 50 mm. 1; 4-
nitrophenol, 2; 4-nitrocatechol, 3; 3-nitrocatechol, 4; 3,5-dinitrocatechol, 5; entacapone, 6;
entacapone(Z)-isomer, 7; nitecapone, 8; tolcapone.
The developed UGT assay was validated with 4-nitrophenol as the substrate. Good cor-
relations between the in situ spectra measured 0.5 mm before and after the 4NPG peak
centre (r=0.9805 and 0.9847, respectively) in conjunction with symmetrical peak shape
(T0.05=1.0) demonstrated that the sample matrix did not interfere with the analysis. The
repeatability of sample application, often a critical stage in quantitative analysis, proved
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to be satisfactory (RSD=2.2%, 50 µM 4NPG, n=7). The limit of quantitation, 15 pmol
4NPG on the plate, representing the lowest concentration at which the RSD of sample
application (n=3) did not exceed 5% (Ferenczi-Fodor et al., 1993), enabled reaction
velocity measurements at low 4NP concentrations. The recoveries of various 4NPG
concentrations (12.5, 50 and 75 µM) spiked in the sample matrix were rather consistent
(95.2±3.4, 102.8±2.5 and 102.0±2.2%, respectively, n=6) and showed a mean value of
100%. The relatively low RSD values (between 4.1 and 11.7%, n=6) achieved at six
initial concentrations of 4-nitrophenol suggested that the within-laboratory reproduci-
bility of the method was at a tolerable level. The good reproducibility of the determina-
tion of the enzyme kinetic parameters K
m
 and V
max
 (RSD 6.1 and 6.3%, respectively,
n=6) indicated that the method was suitable for enzyme kinetic studies.
Lack of reference standards of the different nitrocatechol glucuronides necessitated
the utilisation of 14C-labelled UDPGA in quantitation. However, to decrease the costs
and risks of the analysis, the radioactive cosubstrate was added to just one of the sam-
ples in each kinetic series. The concentration level of the glucuronides was obtained
with this sample and the glucuronides in the other samples were quantitated on the basis
of densitometric analysis. The good correlation (r=0.9920) between the results obtained
for the same 4-nitrophenol samples by this method and by the method utilising 4NPG
demonstrated that reliable results could be obtained in a wide range of glucuronide con-
centrations. In general, the benefits of TLC include low solvent consumption, off-line
character and possibility to analyse several samples simultaneously. Compared with the
traditional UGT assay developed by Bansal and Gessner (1980), the new method was
cost-effective and did not require time-consuming exposure to x-ray films. Although it
is only applicable for compounds exhibiting a reasonably high molecular absorptivity,
all the nitrocatecholic compounds could be analysed under the same conditions. The
main disadvantage of the method, that multiple glucuronides could not be separated, is
shared by all TLC-based UGT assays. However, the idea of a using radioactively la-
belled cosubstrate only for calibrating the product level is applicable for HPLC as well.
This approach was used in a study on chrysene and benzo(a)pyrene phenols in which,
after HPLC separation, quantitation was based on the linear relationship observed be-
tween radioactivity, fluorescence and UV absorption (Bock et al., 1992). Improvement
in sensitivity by combining UV or fluorescence detection with radioactivity measure-
ment may be desired in kinetic studies where a high UDPGA concentration is required,
which decreases the formation of radioactively labelled glucuronides.
5.1.2. Radiochemical high-performance liquid
chromatographic COMT assay (IV, V)
A radiochemical HPLC method for the assay of COMT towards various substrates was
developed with 3,4-dihydroxybenzoic acid (DHBA) as the substrate. The method could
be applied in studying the in vitro methylation of 55 catecholic compounds including
physiological catechols, drugs and drug candidates, and structurally simple catechols.
The mobile phase used for acidic and neutral compounds consisted of a phos-
phate/citrate buffer (pH 3.2) and a varying amount of methanol (3-60%). To increase
the retention of compounds containing basic groups, an ion-pair reagent, 1-
octanesulphonic acid, was added to the buffer. Examples of chromatograms obtained
from different catechol substrates and mobile phase compositions are shown in Fig. 5.
The chromatograms illustrate that the method allowed detection of regioisomeric O-
methylated products formed from many compounds.
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Fig. 5. Chromatograms in the radioactivity detector obtained from samples in which
AdoMet/14C-AdoMet and recombinant human S-COMT were incubated with a) 3,4-
dihydroxybenzoic acid b) dopamine c) L-dopa d) 2-hydroxyestradiol. The column used was a
Hypersil BDS-C18, 125x4 mm, 5 µm, and the proportion of phosphate/citrate buffer (pH 3.2)
and methanol was a) 90:10 b) 85 (including 1.25 mM 1-octanesulphonic acid) :15 c) 95 (in-
cluding 1.25 mM 1-octanesulphonic acid) :5 d) 40:60.
The COMT assay was validated with DHBA as the substrate and recombinant human S-
COMT as the enzyme source. The O-methylated metabolites were quantitated by com-
paring their peak areas in the radioactivity detector with the total area of radioactive
peaks. The results of the validation experiments based on the quantitation of vanillic
acid are summarised in Table 4. The quantitation based on comparison of the area of
radioactive peaks correlated well with the method relying on UV detection. The recov-
ery and the repeatability of the method were good, and the good repeatability of the de-
termination of the enzyme kinetic parameters showed that the method was well suited
for its intended use. When applying the method to other compounds, however, more
variation in for example recovery and stability may be expected. Fortunately, no loss of
total radioactivity, represented by the sum of peak areas in the radioactivity detector,
could be detected among the compounds studied. Stability problems were minimised by
using fresh solutions only, adding antioxidant (L-cysteine) to the reaction mixture and
always analysing the samples immediately after preparation. Earlier published K
m
 val-
ues for DHBA, dopamine, noradrenaline and L-dopa determined by using HPLC with
electrochemical detection are well comparable with those obtained by this method
(Lotta et al., 1995).
Most of the compounds could be analysed with a solid scintillant in the radioactivity
detector. A solid scintillant, earlier utilised in UGT assay (Ethell et al., 1998), has some
advantages compared with on-line liquid scintillation counting. No scintillation liquid
or additional pump is needed, obviating the need to optimise the scintillant/mobile
phase flow rate. The use of a solid scintillant not only reduces costs but also markedly
decreases the production of waste. However, compounds exhibiting low K
m
 values re-
quired improved sensitivity. The limit of detection could be lowered from 9 to 1
pmol/injection by substituting the 300-µl cerium-activated lithium glass cell by a 500-µl
flow cell that received scintillation liquid 3 ml/min. With this modification the sensitiv-
ity level (0.45 pmol) of an earlier COMT assay utilising S-adenosyl-L-[methyl-
3H]methionine and on-line radiochemical detection (Nissinen, 1985) could be reached.
Considerably lower metabolite levels, however, are detectable by electrochemical and
fluorescence detectors (Reenilä et al., 1995, Tuomainen et al., 1996, Zürcher et al.,
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1996), and assays relying on them are methods of choice when COMT activity has to be
measured in erythrocytes or other tissues with low COMT expression. Nevertheless, the
new method utilising 14C-AdoMet and on-line radiochemical detection is suitable for
studies on structure-activity relationships and mechanisms of regioselectivity in which
structurally diverse catecholic compounds are included. The method provides also a
rapid screening assay for the in vitro methylation of for instance new catecholic drug
candidates.
Table 4. Validation of the radiochemical HPLC method for the assay of COMT with 3,4-
dihydroxybenzoic acid as the substrate.
Validation parameter Result
Accuracy of quantitation (5-300 µM DHBA) compared to UV-detection, r2=0.9988 (n=6)
Recovery (300 µM DHBA) 97.5 ± 2.5%, (n=6)
Repeatability
-at different DHBA concentrations (5-300 µM)
-determination of kinetic parameters
RSD= 3.30-7.30% (6 concentrations, n=6)
K
m
: RSD=7.94%, V
max
: RSD =3.57% (n=3)
Limit of detection
-solid cell
-liquid cell
9 pmol/injection at signal/noise = 3
1 pmol/injection at signal/noise = 3
5.2. Glucuronidation of nitrocatechols
5.2.1. Glucuronidation of nitrocatechols by rat liver micr o-
somes (II)
In order to assess the properties of nitrocatechol-type compounds as UGT substrates,
enzyme kinetic parameters were determined for a nitrocatechol series and the model
substrate 4-nitrophenol in rat liver microsomes (Table 5). Microsomes were derived
from male Wistar rats treated with creosote, which, similar to 3-methylcholantherene,
has been found to cause a two-fold induction of 4-nitrophenol glucuronidation (Luuk-
kanen et al., 1997). In this study creosote was found to increase the glucuronidation rate
of entacapone and tolcapone, by approximately two-fold.
Disubstituted COMT inhibitors showed approximately one order of magnitude lower
V
max
/K
m
 values compared with 4-nitrophenol and 4-nitrocatechol. This may be due to
UGT1*06, an isoform known to be induced by 3-methylcholantherene (and possibly by
creosote) and reported to exhibit a restricted specificity towards small and planar phe-
nols (Jackson et al., 1988). Consequently, other isoforms are likely to contribute to the
glucuronidation of the compounds with bulkier substituents. Existence of a parabolic
dependence between glucuronidation rate and lipophilicity has been suggested, with an
optimum value of logP=2.25 for phenolic compounds in rats (Kim, 1991). Although the
glucuronidation rates of 4-n-propylphenol and 4-tert-butylphenol (respective estimated
logP
ow
=3.04 and 3.42) have been reported to be higher than that of 4-nitrophenol (logP
ow
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=1.91) in rat liver microsomes (Jackson et al., 1988), in this study entacapone and tol-
capone (respective logP
ow
=2.22 and 3.13) exhibited approximately five times lower V
max
values than 4-nitrophenol. Apparently other structural features, not identified in this
study, affected the glucuronidation of these COMT inhibitors. Nevertheless, the more
lipophilic nature of tolcapone compared with entacapone and especially nitecapone
(logP
ow
=1.04) may explain its higher affinity towards rat UGTs. The especially high K
m
value obtained for nitecapone may indicate a contribution of a distinct low-affinity iso-
form to the glucuronidation of this compound.
Table 5. Apparent enzyme kinetic parameters for the glucuronidation of 4-nitrophenol and some
nitrocatechols by liver microsomes from creosote-treated rats. The values represent mean ± SD
of three or four independent experiments.
Compound V
max
(nmol min-1 mg-1)
K
m
(mM)
V
max
/K
m
(ml min-1 mg-1)
4-Nitrophenol 68.8±3.8 0.11±0.02 0.63
4-Nitrocatechol 153.0±26.4 0.19±0.05 0.79
3-Nitrocatechol 127.7±15.5 0.72±0.11 0.18
3,5-Dinitrocatechol 36.2±7.7 1.04±0.27 0.035
Entacapone 13.4±2.1 0.75±0.27 0.018
Entacapone(Z)-isomer 15.5±3.4 0.40±0.11 0.039
Nitecapone 52.9±5.9 2.40±0.19 0.022
Tolcapone 11.0±1.5 0.29±0.06 0.038
4-nitrocatechol was a better substrate than 4-nitrophenol, which demonstrates that an
ortho-hydroxyl does not interfere with the binding to the enzyme, and that catechols
may be excellent substrates of UGTs. Substituents in the benzene ring, however, mark-
edly influence the properties catechols exhibit as substrates of UGTs. The four-fold in-
crease in the K
m
 value observed with 3-nitrocatechol compared with 4-nitrocatechol
may be due to steric hindrance. Accordingly, bulky ortho-substituents have been found
to decrease the tendency of phenol glucuronidation in rat and human liver microsomes
(Boutin et al., 1985, Temellini et al., 1991). The even higher K
m
 value of 3,5-
dinitrocatechol compared with 3-nitrocatechol may be caused by the increased nucleo-
philicity of the catecholic hydroxyls. Conclusions about the electronic effects of sub-
stituents cannot, however, be drawn on the basis of this study in which only nitrocate-
chols were included. In general, contradicting results have been published concerning
the electronic effects of substituents (Magdalou et al., 1982, Jackson et al., 1988, Te-
mellini et al., 1991, Kim, 1991, Yin et al., 1994) and proper structure-activity analyses
with individual UGT isoforms are needed to explain them.
The V
max
/K
m
 value, which describes the reaction at low substrate concentration, was
approximately two times higher for tolcapone than the respective value for entacapone.
Consequently, the longer elimination half-life of tolcapone observed in humans in vivo
could not be explained by their glucuronidation kinetics in rat liver microsomes.
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5.2.2. Glucuronidation of entacapone and tolcapone by human
liver microsomes and recombinant UGT isoforms (III)
To characterise the human UGT isoforms involved in the glucuronidation of entacapone
and tolcapone, the COMT inhibitors were incubated with cell lysates containing a repre-
sentative set of recombinant UGT isoforms: UGT1A1, UGT1A6, UGT1A9, UGT2B7,
and UGT2B15 (Fig. 6). Results of the screening revealed that UGT1A9 was the most
important isoform contributing to the glucuronidation of both entacapone and tolca-
pone. Tolcapone was glucuronidated at the same rate by this isoform as the widely used
standard substrate, propofol, whereas entacapone showed almost two-fold velocity
compared with them.
Fig. 6. Glucuronidation velocity of 500 µM entacapone and tolcapone by recombinant human
UGT isoforms. Respective standard substrates for UGT1A1, 1A6, 1A9, 2B7, and 2B15 were
octylgallate, 1-naphthol, propofol, 4-hydroxyestrone, and 8-hydroxyquinoline.
Tolcapone seemed not to be a substrate of the bilirubin isoform UGT1A1, while entaca-
pone was glucuronidated at a low rate by it. According to the known restricted substrate
specificity of UGT1A6 towards small planar phenols (Ebner and Burchell, 1995), nei-
ther entacapone nor tolcapone was glucuronidated by this isoform. Both COMT inhibi-
tors were glucuronidated at low velocities by the representative members of the UGT2B
family, UGT2B7 and UGT2B15.
To compare the kinetic properties of entacapone and tolcapone, apparent enzyme ki-
netic parameters were determined for them using recombinant human UGT isoforms
and human liver microsomes (Table 6). Studies with UGT2B7 revealed K
m
 values in the
millimolar range, which prevented the proper kinetic analysis with this isoform. The
COMT inhibitors seemed to be very similar substrates of UGT2B15, while a qualita-
tively considerable difference was detected with UGT1A1. Tolcapone was not glucu-
ronidated by this isoform, whereas it was the only isoform that catalysed the formation
of two glucuronides of entacapone. The very similar chromatographic behaviour of the
second glucuronide to that of entacapone 3-O-glucuronide (rt 8.4 and 8.9 min, respec-
tively) suggests that it was the 4-O-glucuronide conjugate. The contribution of
UGT1A1 to the glucuronidation of entacapone seems, however, to be minor compared
with that of UGT1A9, which is supported by the fact that only 3-O-glucuronides of en-
tacapone have been found in human urine (Wikberg et al., 1993). Therefore, possibili-
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ties for interactions with the most important physiological UGT1A1 substrate, bilirubin,
are likely to be only theoretical.
Table 6. Apparent kinetic parameters for the formation of 3-O-glucuronides of entacapone and
tolcapone by human liver microsomes (HLM) and recombinant UGT isoforms. The values rep-
resent mean ± SD of two to five determinations.
UGT source V
max
(nmol min-1
mg-1)
Entacapone
K
m
(µM)
V
max
/K
m
(ml min-1 mg-1
x 10-3)
V
max
(nmol min-1
mg-1)
Tolcapone
K
m
(µM)
V
max
/K
m
(ml min-1 mg-1
x 10-3)
HLM 6.8±2.0 47±5 144 2.1±1.1 201±102 10.3
UGT1A1 0.004
0.005a
31
93
0.13
0.05
NDb - -
UGT1A9 1.8±0.6 10.0±1.9 182 0.48±0.15 66±12.0 7.3
UGT2B7c 0.007 1800 0.004 0.013 640 0.020
UGT2B15 0.024 322 0.08 0.024 429 0.06
aAnother glucuronide of entacapone detected, most probably 4-O-glucuronide
bND=not detected
cNo proper kinetic analysis could be performed due to low activity and high substrate concentration
needed
Comparable variation in the kinetic parameters of entacapone and tolcapone by
UGT1A9 and human liver microsomes (3- to 4-fold V
max
 and 4-6 times lower K
m
 for
entacapone) suggest that this particular isoform might be mainly responsible for the dif-
ferences in the overall glucuronidation of these compounds (Fig. 7, Table 6). Particu-
larly strong involvement of UGT1A9 was further supported by the high glucuronidation
rates measured in kidney microsomes (2.31 and 0.763 nmol min-1 mg-1 for entacapone
and tolcapone, respectively), since this isoform is richly expressed in the kidney (Suth-
erland et al., 1993, McGurk et al., 1998). The finding is also consistent with the previ-
ous observations on the wide substrate acceptance of UGT1A9 including phenolic and
carboxyl-acid containing drugs (Ebner and Burchell, 1993, Wooster et al., 1993). No
obvious reason for the reduction of the reaction velocity by UGT1A9 at high entaca-
pone concentration (Fig. 7) could be discovered, yet fitting of the equation for substrate
inhibition resulted in the V
max
/K
m
 value close to that derived from the Michaelis-Menten
equation (156 and 144 ml min-1 mg-1). Nevertheless, this phenomenon was not observed
with liver microsomes and should exhibit no significance at physiological concentra-
tions. The finding that UGT1A9 is probably the most relevant isoform in the glucuroni-
dation of entacapone and tolcapone may be, although no metabolic interactions with
entacapone nor tolcapone have been reported, of great help in assessing possibilities for
them.
Compared with tolcapone, entacapone exhibited more than three-fold V
max
 and four
times lower K
m
 value in human liver microsomes, leading to about 14-fold V
max
/K
m
value. The differences in in vitro glucuronidation kinetics relate to in vivo observations
showing that entacapone is almost exclusively metabolised by glucuronidation (Wik-
berg et al., 1993), while, although glucuronidation is the main pathway, also other
routes significantly contribute to the metabolism of tolcapone (Jorga et al., 1999a). Be-
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cause both compounds are almost completely eliminated by metabolism, glucuronida-
tion kinetics may also partly explain the shorter elimination half-life of entacapone
compared with tolcapone. Evaluation of the structural features determining the variation
in the glucuronidation ability of these closely related compounds is, however, hindered
by lack of knowledge on the structure-activity relationships of UGTs.
Fig. 7. Michaelis-Menten plots for the glucuronidation of entacapone and tolcapone by human liver mi-
crosomes and by human UGT1A9. The dashed line represents fitting of the equation for substrate inhibi-
tion.
Although in vitro/in vivo correlation was not a subject of this study, it is interesting to
note that the microsomal clearance (V
max
/K
m
) of entacapone, scaled for the whole liver
with the following assumptions: 77 mg/microsomal protein/g liver, 1800 g liver/human,
liver blood flow 1.45 l/min (Pelkonen 1999, Davies et al, 1993), gives a hepatic clear-
ance value of 1.35 l/min. Conversion of the in vivo plasma clearance value reported for
entacapone (750 ml/min) (Keränen et al., 1993) to blood clearance value, by dividing it
with the blood/plasma partitioning value of 0.6, gives 1.25 l/min. The good correspon-
dence of these values, although calculated from insufficient data (for example the clear-
ance by extrahepatic tissues and other metabolism routes were excluded and a micro-
some pool from six individuals only was used), indicate that in the case of entacapone
the in vitro results may at least be suggestive of the in vivo situation.
5.2.3. Species differences
An obvious discrepancy in the glucuronidation kinetics of entacapone and tolcapone
was detected between the results obtained from rat and human liver microsomes. The
most relevant enzyme kinetic parameter V
max
/K
m
 was two times higher for tolcapone
than for entacapone in rat liver microsomes, while in human liver microsomes entaca-
pone, with a 14-fold V
max
/K
m 
value, was demonstrated to be superior over tolcapone.
Species differences have also appeared in the in vivo metabolism of entacapone; in hu-
mans over 95% of the metabolites excreted in the urine 0-2 h after administration were
glucuronides of entacapone and its (Z)-isomer, whereas in the rat only approximately
65% of the metabolites represented glucuronide conjugates and almost 10% were sul-
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phates (Wikberg et al, 1993). Therefore, based on both in vivo and in vitro data, rat
seems not to be a good animal model for predicting the glucuronidation of this type of
compound in humans. This may concern all the compounds glucuronidated mainly by
UGT1A9, since predominant in vivo excretion as sulphate conjugates and low glucu-
ronidation activity in liver microsomes have been reported for propofol in the rat (Le
Guellec et al., 1995, Simons et al., 1991), while in humans its main metabolic pathway
is glucuronidation, which is also supported by the high in vitro glucuronidation rate
measured in liver microsomes (Simons et al., 1988, Le Guellec et al., 1995).
5.3. Substrate selectivity of rat and human S-COMT (IV,
V)
The three dimensional structure of rat S-COMT has been solved by crystallography
(Vidgren et al., 1994). In order to evaluate its applicability for modelling human S-
COMT, enzyme kinetic parameters of 17 catecholic compounds were determined using
recombinant rat and human S-COMT. For the first time substrate selectivity of rat and
human S-COMT was determined under the same experimental conditions thus allowing
a proper comparison. The enzymes exhibited very similar regioselectivities and both the
K
m
 and V
max
 values, determined for the same catechols, were highly correlated (r2=0.988
and r2=0.927, respectively, n=25, including regioisomers). This is in agreement with the
high sequence homology (81%) of the enzymes and the almost completely conserved
amino-acid residues in the active site (Vidgren and Ovaska, 1997). The absolute V
max
values obtained using rat and human S-COMT were not comparable, since concentra-
tions of active enzyme were not known, but the K
m
 values showed 3-4 times higher fig-
ures for the rat enzyme, on average. It is possible that the rat enzyme, although ex-
pressing similar mechanisms for substrate selectivity, possesses a somehow looser ac-
tive site structure thereby decreasing the affinity of substrate binding.
Fig. 8. Correlation of reaction velocities (nmol min-1 mg-1) between human and rat S-COMT
(r2=0.858, n=30). The dashed line represents the correlation without gallic acid, pyrogallol and
catechin (r2=0.960, n=27).
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When rat and human S-COMT activity was screened at one relatively high concentra-
tion (IV, 500 µM) discarding three outliers (gallic acid, pyrogallol and catechin) from
the analysis improved correlation from r2=0.858 (n=30) to r2=0.960 (n=27) (Fig. 8). Py-
rogallol derivatives are low-affinity inhibitors of COMT and at the high concentration
used they inhibited their own methylation. The higher affinity towards the human en-
zyme appeared as a more pronounced inhibition of the human enzyme than of the rat
enzyme, which probably explains the deviation from the correlation. Despite the kinetic
difference, rat S-COMT proved to be an excellent model for the human enzyme thereby
validating its use as a template in computer-aided molecular modelling.
5.4. Methylation of structurally diverse compounds by
human S-COMT (V)
5.4.1. Enzyme kinetic parameters
Methylation of 46 structurally diverse catechols was investigated using recombinant
human S-COMT to obtain data for structure-activity analysis. The enzyme kinetic pa-
rameters could be determined for 41 compounds including simple substituted and
physiological catechols and catecholic drugs and drug candidates (Tables 7-8).
Under the conditions used, no methylation of 3,5-dinitrocatechol, 2,3-
dihydroxybenzoic acid, tolcapone, entacapone, or apomorphine was observed. Two re-
gioisomeric products could be detected from many of the compounds, yet the analytical
method utilising 14C-AdoMet did not allow elucidation of the metabolite structures.
However, the enzyme kinetic parameters were determined separately for both isomers
when possible and useful experimental data about regioselectivity, that supported ob-
servations derived from molecular modelling, could be gathered. Pyrogallol and cate-
chol showed the highest V
max
 values (53.2 and 48.9 nmol min-1 mg-1), while the lowest
measurable V
max
 was 0.15 nmol min-1 mg-1 for 3-nitrocatechol. Among the series of sub-
stituted catechols in Table 7, catechol exhibited the highest K
m
 value (50 µM). This
value was more than three orders of magnitude higher than the lowest value obtained
(29 nM, for tetrachlorocatechol). Nevertheless, many endogenous and other catechols
with pharmacological activity exhibited several-fold higher K
m
 values than catechol
(Table 8). The V
max
/K
m
 values were highest for tetrachlorocatechol and 2,3-
dihydroxynaphthalene.
Among the endogenous catechols 2- and 4-hydroxyestradiols were superior COMT sub-
strates; they exhibited high V
max
 values and low K
m
 values leading to, for instance, ap-
proximately 60- and 10-fold V
max
/K
m
 values compared with dopamine, respectively.
Among drugs used in the treatment of Parkinson’s disease, entacapone and tolcapone
were not methylated in vitro and L-dopa and carbidopa were poor substrates with re-
spective V
max
/K
m
 values of 0.053 and 0.024 ml min-1 mg-1, while the other DDC inhibitor,
benserazide, showed V
max
 and K
m
 values equal to those of catechol. Differences found
between carbidopa and benserazide are in agreement with the previous in vitro results
obtained with COMT purified from pig liver (Hagan et al., 1980, Gordonsmith et al.,
1982). In vitro results also support the in vivo observations concerning the effect of
COMT inhibition by tolcapone on the pharmacokinetics of these compounds; no inter-
actions were detected with carbidopa, whereas the bioavailability of benserazide was
enhanced by tolcapone at large L-dopa/benserazide doses (Sedek et al., 1993, Jorga et
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al., 1999b, Jorga et al., 1999c). Among the other clinically used drugs dobutamine was
a relatively good and isoprenaline a moderately good COMT substrate, whereas α-
methyldopa showed the highest K
m
 value (1.8 mM) among all 41 compounds. These
findings are in agreement with the knowledge on their preferential metabolism routes in
vivo (Table 1). Even though apomorphine has been reported to be a good substrate of rat
liver COMT in vitro (Cannon et al., 1972), and its elimination half-life in rats is in-
creased by tolcapone (Coudore et al., 1997), no methylation was detected under the ex-
perimental conditions applied. In vitro observations may not always correspond to the
in vivo situation, as exemplified by tolcapone that, despite showing no implications for
methylation in our study, has been reported to undergo biotransformation to 3-O-
tolcapone in vivo (e.g. Dingemanse et al., 1995). On the other hand, in a study on the
metabolism of intravenously administered apomorphine in a Parkinsonian patient, no
methylated products were found in plasma or urine (van der Geest et al., 1997). In our
study, apomorphine was demonstrated to inhibit the methylation of DHBA (Ki=240 µM
for competitive inhibition) and thus shown to be capable of binding to the enzyme.
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Table 7. Apparent enzyme kinetic parameters for the methylation of substituted catechols cata-
lysed by recombinant human S-COMT.
Compound V
max
(nmol min-1 mg-1)
K
m
(µM)
V
max
/K
m
(ml min-1 mg-1)
Catechol 48.9±0.9 49.7±1.6 0.98
4-Methylcatechol 24.4±0.9
23.3±1.1
29.1±3.9
36.7±3.3
0.84
0.63
4-Isopropylcatechol 36.3±1.7
6.9±1.5
26.1±3.0
40.5±27.4
1.39
0.17
4-tert-Butylcatechol 41.9±2.7 31.9±8.0 1.31
4-Chlorocatechol 36.0±0.1 11.7±0.5 3.08
3,4-Dihydroxyacetophenone 9.8±0.7 1.4±0.3 7.00
3,4-Dihydroxybenzoic acid ethyl ester 7.2±1.7
3.5±1.1
0.66±0.17
0.66±0.17
10.9
5.30
4-Nitrocatechol 0.77±0.09
0.78±0.05
0.12±0.02
0.12±0.02
6.42
6.50
4-tert-Butyl-5-methoxycatechol 32.5±2.4 18.5±2.3 1.76
Pyrogallol 53.2±1.5 10.4±0.6 5.12
3-Nitrocatechol 0.15±0.02 0.020±0.001 7.50
3-Fluorocatechol 30.7±1.8 7.8±1.0 3.94
3-Methoxycatechol 39.8±1.8 24.5±2.8 1.62
3-Methoxy-5-bromocatechol 17.3±0.9 2.5±0.4 6.92
Methylgallate 11.7±0.4 1.0±0.1 11.7
3,5-Dinitrocatechol ND
3,4-Dihydroxybenzoic acid 35.6±0.9
7.7±0.1
19.9±2.0
28.3±0.4
1.79
0.27
2,3-Dihydroxybenzoic acid ND
Caffeic acid 25.9±1.9
15.5±0.2
3.2±0.7
2.8±0.1
8.09
5.54
Hydrocaffeic acid 31.5±1.7
12.1±0.03
25.4±4.5
45.1±0.3
1.24
0.27
Tetrachlorocatechol 0.62±0.03 0.029±0.002 21.4
2,3-Dihydroxynaphthalene 30.8±1.6 1.5±0.3 20.5
6,7-Dihydroxycoumarin 3.3±0.03 0.30±0.01 11.0
ND = not detected
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Table 8. Apparent enzyme kinetic parameters for the methylation of some endogenous cate-
chols, catecholic drugs and drug candidates catalysed by recombinant human S-COMT.
Compound V
max
(nmol min-1 mg-1)
K
m
(µM)
V
max
/K
m
(ml min-1 mg-1)
L-Noradrenaline 33.2±0.8 256±20 0.13
3,4-Dihydroxymandelic acid 43.7±2.0 132±11 0.33
3,4-Dihydroxyphenylglycol 37.2±1.4 46.4±4.7 0.80
L-Adrenaline 44.0±1.0 132±13 0.33
Dopamine 35.9±1.4 188±16 0.19
5-Hydroxydopamine 46.7±1.1 61.6±4.1 0.76
6-Hydroxydopamine 25.3±2.0 244±32 0.10
3,4-Dihydroxyphenyl acetic acid 34.0±2.2
4.0±0.1
68.8±10.8
53.7±4.0
0.49
0.074
2-Hydroxyestradiol 32.4±2.6
13.7±1.8
3.7±1.1
4.2±2.2
8.76
3.26
4-Hydroxyestradiol 31.5±2.5 12.4±2.6 2.54
α-Methyldopa 21.4±0.7
2.6±0.3
1789±108
1170±309
0.012
0.002
L-dopa methylester 44.2±0.7 51.1±2.9 0.86
L-dopa 29.8±0.9 564±28 0.053
S(-)-Carbidopa 14.3±0.8 599±63 0.024
Benserazide 41.8±3.6 50.2±7.2 0.83
Tolcapone ND
Entacapone ND
Isoprenaline 25.8±0.6
3.1±0.3
145±8.5
170±31
0.18
0.018
Dobutamine 29.0±0.9
6.9±0.5
23.7±3.1
28.6±7.5
1.22
0.24
1-Methyl-6,7-dihydroxy-1,2,3,4-
tetrahydroisoquinoline
18.3±0.9
10.6±0.1
29.4±3.7
36.2±0.2
0.62
0.29
SKF 38393 5.0±0.04
10.5±0.5
67.2±1.2
73.6±8.3
0.074
0.14
Dihydrexidine 10.1±2.3
10.5±6.2
25.0±14.5
53.1±50.6
0.40
0.20
Apomorphine ND
ND = not detected
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5.4.2. Effect of molecular structure on binding affinity and r e-
activity
Combining experimental data, molecular modelling and calculated data on substituent
physico-chemical properties, mechanisms affecting binding affinity and reactivity could
be elucidated. The most important substituent effects identified in this study were the
electronic effect on catecholic hydroxyls, interactions with the surroundings of the cate-
chol binding groove, steric hindrance, especially by ortho-substituents, and some other
ortho-effects.
In this study, the most important factor affecting reactivity appeared to be the elec-
tron-withdrawing effect of substituents. The electronic effect of substituents is best
demonstrated by a set of small 4-substituted compounds that exhibit a minimum amount
of direct interactions with the amino acid residues in the binding site (the first eight
compounds in Table 7). Their V
max
 values were highly correlated with parameters de-
scribing electronic effects of the substituents. Hammet σ - value, which quantitates the
effect of a 4-substituent on the ionisation of phenol, explained 94% of the variation in
the V
max
 values, and even better correlation (r2=0.98) was achieved when the lower mo-
lecular electrostatic potentials (MEP) were calculated for the monoanionic forms of the
compounds. A semiempirical study on COMT inhibition has suggested that the reason
for lowered reactivity by electronegative substituents is stabilisation of the catecholate
anion, formed via proton transfer to the amino group of Lys 144 (Ovaska and
Yliniemelä, 1998). The catecholate anion-enzyme complex, rather than the transition
state complex, is stabilised leading to a high energy barrier for methylation. As expected
on the basis of QSAR studies on COMT inhibition (Taskinen et al., 1989, Lotta et al.,
1992), results of this study showed that binding affinity was increased by electronega-
tive substituents as well. The Hammet σ - value and MEP explained 94 and 97%, re-
spectively, of the variation in log(1/K
m
) values among the eight 4-substituted catechols.
Direct interactions of the catechols with the surroundings of the binding site were eluci-
dated by superimposing the compounds on 3,5-dinitrocatechol in the crystal structure of
rat S-COMT. Favourable and unfavourable interactions with the hydrophobic amino
acid residues lining the catechol binding site could be observed. In general, hydrophobic
substituents increased the affinity, as exemplified by the lowered K
m
 values of 4-
alkylsubstituted catechols and 2,3-dihydroxynaphathlene compared with catechol. The
most favourable interactions were formed with 2-hydroxyestradiol that has a flat fused
ring structure filling optimally the binding pocket (Fig. 9). The higher K
m
 values ob-
tained for other compounds with a fused ring structure compared with hydroxyestradiols
were obviously due to the unfavourable interactions caused by the ionised amino group.
In apomorphine the amino group is in such an orientation that it should not affect the
binding. However, its bulky ortho-substituent overlaps severely one of the surrounding
residues (Trp143). The methyl group of AdoMet is also overlapped, which may cause
the observed loss of reactivity. Inhibition of the COMT-catalysed methylation of DHBA
by apomorphine revealed that binding of apomorphine is possible, yet conformational
changes of the enzyme are required.
The positively charged side chain of catecholamines (e.g. dopamine) has been sug-
gested to interact unfavourably with the hydrophobic amino acids in the active site
thereby lowering the affinity (Lotta et al., 1995). However, the side chain is flexible and
may be in an orientation in which interactions are avoided. In this study, hydrocaffeic
acid exhibited almost one order of magnitude lower K
m 
compared with that of dopa-
mine, although the flexibility of the oppositely charged side chains of these compounds
should be similar. Fitting of 27 low energy conformers of dopamine to the active site
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revealed that most of them had the amino group overlapping or in contact with the ac-
tive site residues. In the case of hydrocaffeic acid, however, most of the 31 low energy
conformations had the carboxyl group pointing out from the binding site or at least in
orientations with fewer contacts with the binding site. Consequently, the allowed or fa-
voured conformations seemed to determine the affinity of compounds with flexible
ionised side chains towards S-COMT. The high K
m
 values of L-dopa and α-methyldopa
(Table 8) suggest that compounds that have a crowded side chain with two polar groups
exhibit especially unfavourable interactions with the binding site residues.
Fig. 9. Structural formulae of compounds with a fused ring system.
A nitro group in 3-nitrocatechol has been reported to increase the binding affinity even
more than expected from its strong electronic effect (Taskinen et al., 1989). Accord-
ingly, a six times lower K
m
 value was obtained for 3-nitrocatechol than for 4-
nitrocatechol in this study (0.02 and 0.12 µM, respectively). A nitro group at the 3-
position probably exhibits favourable hydrophobic and van der Waal interactions with
the binding site. Another ortho-substituent that improved affinity was a hydroxyl group;
pyrogallol showed a five times lower K
m
 compared with catechol and the K
m
 of 5-
hydroxydopamine was four times lower than that of 6-hydroxydopamine. Since no
group capable of hydrogen bonding is located in the contact distance with the ortho-
hydroxyl, a plausible reason for the increased affinity may be an exceptionally favour-
able van der Waals interaction. A carboxyl acid group in the ortho-position decreased
the affinity by one order of magnitude as exemplified by the Ki and Km values of 2,3-,
and 3,4-dihydroxybenzoic acid (380 and 20 µM, respectively). The carboxylate group
fits sterically to the binding site, but the impaired affinity is obviously due to the unfa-
vourable interactions caused by the ionised group. The carboxylate anion may also in-
terfere with the catalytic machinery of the reaction and thereby cause the complete loss
of reactivity.
Although the structures of the methylated compounds were not confirmed, sugges-
tion of the preferential methylation site could be derived from the sterical fit of the two
alternative binding modes. Tetrachlorocatechol was methylated at a low rate and, in
conjunction with 2-methoxy-3-fluorophenol, a small amount of 2-fluoro-6-
methoxyphenol was formed from 3-fluorocatechol, which suggests that small substitu-
ents can be accommodated in the R6 position. However, ortho-substitution seems to
direct a catechol preferentially to the binding orientation that results in the methylation
of the hydroxyl next to the substituent. Consistently, only one major product was de-
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tected for pyrogallol derivatives and other 3-substituted catechols. One metabolite was
formed also from 4-hydroxyestradiol, while two metabolites with similar affinity were
detected for 2-hydroxyestradiol. The relatively bulky ortho-substituent in 4-
hydroxyestradiol seems to direct the binding to the orientation that leads to the meth-
ylation of the hydroxyl next to it. Different kinds of interactions of the side chain with
the binding site residues at different binding modes can explain the regioselectivity of
many compounds. For example, catecholamines obviously bind predominantly in the
orientation resulting in the m-methylation because of less unfavourable interactions in
this orientation, as previously suggested by Lotta et al. (1995). Compared with the steric
factors, the electronic effects of the substituents seem to have a minor contribution to
regioselectivity. In studies on ring-fluorinated catecholamines, ortho-fluorine has been
suggested to facilitate methylation of the adjacent hydroxyl by increasing its ionisation
(Firnau et al., 1981, Creveling et al., 1981, Thakker et al., 1986). However, it is now
known that electronegative substituents conversely decrease reactivity, and the reason
for the altered regioselectivity may be the steric ortho-effect discussed above.
5.4.3. Predictive models
The most decisive factor determining the reactivity of a compound was the electronic
effect of the substituents on the catechol hydroxyls. The volume of an isoenergy MEP
was used to describe the electronic effects, because this parameter can be readily calcu-
lated for any substrate. In the case of neutral compounds (n=20), MEP, calculated for
the catecholate monoanion exhibiting the lower minimum, could explain over 93% of
the variation in the V
max
 values. The correlation clearly deteriorated when compounds
containing ionisable side chains were included (r2=0.705, n=38). However, ionisable
groups are expected to affect the acidity of the catechol hydrogens to a small extent
only, and the V
max
 of this kind of compound can be predicted to be near as that of unsub-
stituted catechol. Deterioration of correlation between MEP and V
max
 was probably
caused by the poor steric fit of some compounds to the active site. Therefore, for pre-
dicting V
max
 both calculation of the electronic effect and modelling of the compound to
the active site are required.
Besides the electronic effect of the substituents, hydrophobicity of a catechol ap-
peared to be an important factor in predicting affinity. LogK
ow
 values were calculated by
the LOGKOW method, because the method is rapid and has been shown to correlate
well with experimental values (Meylan and Howard, 1995). In the two parameters’ re-
gression model (2), the logK
ow
 values were calculated for the compounds with their side
chain in ionised form.
(2) log(1/K
m
) = -0.30(±0.03) MEP
vol + 0.21(±0.03) logKow + 6.99(±0.23)
The correlation between the calculated and observed log(1/K
m
) values was r2=0.833
(n=38), and the leave-five-out cross-validation gave r2=0.782. Although the model ex-
cludes for example the pronounced unfavourable effects of polar groups caused by
steric crowding (e.g. α-methyldopa) and the increased affinity caused by an ortho-
hydroxyl, the affinity of a catechol may be predicted with reasonable accuracy. Moreo-
ver, most steric and conformational effects may be evaluated by fitting the compound to
the crystal structure of rat S-COMT.
The predictive models constructed in this study, supported by modelling of the active
site, may be utilised in evaluating the interactions between endogenous and exogenous
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catechols (e.g. dietary compounds and drugs) and in designing new catecholic drugs
with controlled metabolic methylation.
Conclusions
An HPTLC method combining densitometry and radioactivity measurement was devel-
oped for the study of the in vitro glucuronidation of nitrocatechols. These types of com-
pounds may be excellent substrates of rat liver UGTs, but the position and nature of
substituents greatly affect their glucuronidation. Nitrocatechols with large substituents,
such as entacapone and tolcapone, exhibited one order of magnitude lower V
max
/K
m
 val-
ues compared with smaller ones in microsomes from creosote-treated rats. Tolcapone
exhibited a two-fold V
max
/K
m
 value compared with entacapone. In contrast, entacapone
was shown to be a clearly better UGT substrate in human liver microsomes suggesting
that the rat is a poor model for predicting the glucuronidation of these compounds in
humans. Since both entacapone and tolcapone are rapidly glucuronidated in vivo, the
14-fold V
max
/K
m 
for entacapone in human liver microsomes may explain some of its ap-
proximately seven times shorter elimination half-life. Both compounds, but particularly
entacapone, appeared to be excellent substrates of UGT1A9, knowledge which may be
utilised in assessing the risks for metabolic interactions. More knowledge on the struc-
ture-activity relationships of individual UGT isoforms is required for the evaluation of
the structural features turning these COMT inhibitors to such good UGT substrates and
causing the differences between them.
A radiochemical HPLC method for the assay of COMT activity towards structurally
diverse catechols was developed. Enzyme kinetic parameters were determined for 41
catechols using human S-COMT. Of all the compounds, tetrachlorocatechol and 2,3-
dihydroxynaphthalene exhibited the highest V
max
/K
m
 values, while hydroxyestrogens
were the most specific physiological substrates. Catecholic drugs showed variable
methylation ability. For instance among drugs used in the treatment of Parkinson’s dis-
ease, entacapone and tolcapone were not detectably methylated, L-dopa and carbidopa
showed low affinity towards COMT, while benserazide appeared to be a good substrate
of COMT. Electronic factors were found to be the most decisive substituent effect de-
termining the reactivity of the catecholic hydroxyls. Electron-withdrawing substituents
not only decreased reactivity but also increased affinity. The affinity was improved by
hydrophobic substituents as well, whereas hydrophilic side chains deteriorated it. In the
case of substrates with flexible side chains the favoured conformations seemed to de-
termine the affinity. As demonstrated with apomorphine, bulky ortho-substituents de-
creased the affinity and reactivity. In contrast, an ortho-hydroxyl enhanced the meth-
ylation. An ortho-substituent generally directed the methylation to the hydroxyl next to
it. Predictive models were constructed for reactivity, comprising the electronic effect on
catechol hydroxyls, and for affinity, including also a factor describing hydrophobicity.
The models may be utilised, supported by modelling of the active site, in evaluating in-
teractions between catecholic compounds or in designing catecholic drugs with con-
trolled metabolic methylation.
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